[
  {
    "chunk_id": "chunk_ab30a0b877bd",
    "chunk_index": 0,
    "text": "1.1 Adverse Drug Reaction (ADR): In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions.",
    "char_count": 309,
    "word_count": 47,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.1",
      "section_title": "Adverse Drug Reaction (ADR): In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_963bc1483252",
    "chunk_index": 1,
    "text": "1.2 Adverse Event (AE): Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.",
    "char_count": 219,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.2",
      "section_title": "Adverse Event (AE): Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fa57e07f5e0e",
    "chunk_index": 2,
    "text": "1.5 Approval (in relation to Institutional Review Boards): The affirmative decision of the IRB that the clinical trial has been reviewed and may be conducted at the institution site within the constraints set forth by the IRB, the institution, Good Clinical Practice (GCP), and the applicable regulatory requirements.",
    "char_count": 317,
    "word_count": 48,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.5",
      "section_title": "Approval (in relation to Institutional Review Boards): The affirmative decision of the IRB that the clinical trial has been reviewed and may be conducted at the institution site within the constraints set forth by the IRB, the institution, Good Clinical Practice (GCP), and the applicable regulatory requirements.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e9c45f87569d",
    "chunk_index": 3,
    "text": "1.6 Audit: A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's standard operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).",
    "char_count": 381,
    "word_count": 50,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.6",
      "section_title": "Audit: A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's standard operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c347b5729143",
    "chunk_index": 4,
    "text": "1.11 Case Report Form (CRF): A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject.",
    "char_count": 184,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.11",
      "section_title": "Case Report Form (CRF): A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b3f8c99f19df",
    "chunk_index": 5,
    "text": "1.12 Clinical Trial/Study: Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s).",
    "char_count": 194,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.12",
      "section_title": "Clinical Trial/Study: Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b384d0f3c804",
    "chunk_index": 6,
    "text": "1.14 Compliance (in relation to trials): Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements.",
    "char_count": 176,
    "word_count": 22,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.14",
      "section_title": "Compliance (in relation to trials): Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ef8f2bcdfc6c",
    "chunk_index": 7,
    "text": "1.15 Confidentiality: Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity.",
    "char_count": 152,
    "word_count": 20,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.15",
      "section_title": "Confidentiality: Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_10a35efbc448",
    "chunk_index": 8,
    "text": "1.16 Contract: A written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations.",
    "char_count": 178,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.16",
      "section_title": "Contract: A written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0cdf749ff28a",
    "chunk_index": 9,
    "text": "1.18 Coordinating Investigator: An investigator assigned the responsibility for the coordination of investigators at different centres participating in a multicentre trial.",
    "char_count": 172,
    "word_count": 21,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.18",
      "section_title": "Coordinating Investigator: An investigator assigned the responsibility for the coordination of investigators at different centres participating in a multicentre trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_890730342097",
    "chunk_index": 10,
    "text": "1.19 Contract Research Organization (CRO): A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions.",
    "char_count": 203,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.19",
      "section_title": "Contract Research Organization (CRO): A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c179d59dcca3",
    "chunk_index": 11,
    "text": "1.20 Direct Access: Permission to examine, analyze, verify, and reproduce any records and reports that are important to evaluation of a clinical trial.",
    "char_count": 151,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.20",
      "section_title": "Direct Access: Permission to examine, analyze, verify, and reproduce any records and reports that are important to evaluation of a clinical trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_269d8a004ae4",
    "chunk_index": 12,
    "text": "1.21 Documentation: All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken.",
    "char_count": 298,
    "word_count": 44,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.21",
      "section_title": "Documentation: All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4d35c9e90538",
    "chunk_index": 13,
    "text": "1.22 Essential Documents: Documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced.",
    "char_count": 153,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.22",
      "section_title": "Essential Documents: Documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c59af976194d",
    "chunk_index": 14,
    "text": "1.23 Good Clinical Practice (GCP): A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected.",
    "char_count": 330,
    "word_count": 46,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.23",
      "section_title": "Good Clinical Practice (GCP): A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4a4c84c202b5",
    "chunk_index": 15,
    "text": "1.24 Independent Data-Monitoring Committee (IDMC): An independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints.",
    "char_count": 241,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.24",
      "section_title": "Independent Data-Monitoring Committee (IDMC): An independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3abd99927ba6",
    "chunk_index": 16,
    "text": "1.26 Independent Ethics Committee (IEC): An independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical professionals and non-medical members.",
    "char_count": 208,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.26",
      "section_title": "Independent Ethics Committee (IEC): An independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical professionals and non-medical members.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9c2a6c1e950e",
    "chunk_index": 17,
    "text": "1.27 Informed Consent: A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate.",
    "char_count": 248,
    "word_count": 40,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.27",
      "section_title": "Informed Consent: A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c89972de845e",
    "chunk_index": 18,
    "text": "1.28 Inspection: The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial.",
    "char_count": 222,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.28",
      "section_title": "Inspection: The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7358ce32f5b0",
    "chunk_index": 19,
    "text": "1.30 Institutional Review Board (IRB): An independent body constituted of medical, scientific, and non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial.",
    "char_count": 247,
    "word_count": 35,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.30",
      "section_title": "Institutional Review Board (IRB): An independent body constituted of medical, scientific, and non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_60cc768a0eb2",
    "chunk_index": 20,
    "text": "1.31 Interim Clinical Trial/Study Report: A report of intermediate results and their evaluation based on analyses performed during the course of a trial.",
    "char_count": 153,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.31",
      "section_title": "Interim Clinical Trial/Study Report: A report of intermediate results and their evaluation based on analyses performed during the course of a trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_61fc1e5c8713",
    "chunk_index": 21,
    "text": "1.34 Investigator / Institution: An expression meaning \"the investigator and/or institution, where required by the applicable regulatory requirements\".",
    "char_count": 151,
    "word_count": 18,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.34",
      "section_title": "Investigator / Institution: An expression meaning \"the investigator and/or institution, where required by the applicable regulatory requirements\".",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2ec317d32ae7",
    "chunk_index": 22,
    "text": "1.35 Investigator's Brochure: A compilation of the clinical and nonclinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human subjects.",
    "char_count": 198,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.35",
      "section_title": "Investigator's Brochure: A compilation of the clinical and nonclinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c7a87b1d97af",
    "chunk_index": 23,
    "text": "1.36 Legally Acceptable Representative: An individual or juridical or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical trial.",
    "char_count": 214,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.36",
      "section_title": "Legally Acceptable Representative: An individual or juridical or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_64059f9d3362",
    "chunk_index": 24,
    "text": "1.37 Monitoring: The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).",
    "char_count": 280,
    "word_count": 40,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.37",
      "section_title": "Monitoring: The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_84879876b10e",
    "chunk_index": 25,
    "text": "1.38 Monitoring Report: A written report from the monitor to the sponsor after each site visit and/or other trial-related communication according to the sponsor's SOPs.",
    "char_count": 168,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.38",
      "section_title": "Monitoring Report: A written report from the monitor to the sponsor after each site visit and/or other trial-related communication according to the sponsor's SOPs.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_007a766bad51",
    "chunk_index": 26,
    "text": "1.45 Quality Assurance (QA): All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).",
    "char_count": 286,
    "word_count": 41,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.45",
      "section_title": "Quality Assurance (QA): All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d69bf43d2b39",
    "chunk_index": 27,
    "text": "1.46 Quality Control (QC): The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled.",
    "char_count": 212,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.46",
      "section_title": "Quality Control (QC): The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_63bee1964e8c",
    "chunk_index": 28,
    "text": "1.47 Randomization: The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias.",
    "char_count": 171,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.47",
      "section_title": "Randomization: The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_41b7fbd3ee12",
    "chunk_index": 29,
    "text": "1.48 Regulatory Authorities: Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory Authorities includes the authorities that review submitted clinical data and those that conduct inspections.",
    "char_count": 225,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.48",
      "section_title": "Regulatory Authorities: Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory Authorities includes the authorities that review submitted clinical data and those that conduct inspections.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_56fa46067ff7",
    "chunk_index": 30,
    "text": "1.49 Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR): Any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.",
    "char_count": 349,
    "word_count": 45,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.49",
      "section_title": "Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR): Any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5e3ce1547c16",
    "chunk_index": 31,
    "text": "1.50 Source Data: All information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.",
    "char_count": 232,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.50",
      "section_title": "Source Data: All information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ffbcc82401ad",
    "chunk_index": 32,
    "text": "1.51 Source Documents: Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial).",
    "char_count": 549,
    "word_count": 69,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.51",
      "section_title": "Source Documents: Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2377b129cd68",
    "chunk_index": 33,
    "text": "1.52 Sponsor: An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial.",
    "char_count": 163,
    "word_count": 21,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.52",
      "section_title": "Sponsor: An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bb3fc4c89467",
    "chunk_index": 34,
    "text": "1.53 Sponsor-Investigator: An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject.",
    "char_count": 233,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.53",
      "section_title": "Sponsor-Investigator: An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f2a834b1f811",
    "chunk_index": 35,
    "text": "1.55 Subinvestigator: Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions.",
    "char_count": 227,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.55",
      "section_title": "Subinvestigator: Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_446c334c5376",
    "chunk_index": 36,
    "text": "1.56 Subject/Trial Subject: An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control.",
    "char_count": 152,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.56",
      "section_title": "Subject/Trial Subject: An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b239767c5eee",
    "chunk_index": 37,
    "text": "1.57 Subject Identification Code: A unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name when the investigator reports adverse events and/or other trial related data.",
    "char_count": 255,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.57",
      "section_title": "Subject Identification Code: A unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name when the investigator reports adverse events and/or other trial related data.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_420269afdb31",
    "chunk_index": 38,
    "text": "1.58 Trial Master File: The essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.",
    "char_count": 164,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.58",
      "section_title": "Trial Master File: The essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9c0ccc280574",
    "chunk_index": 39,
    "text": "1.60 Unexpected Adverse Drug Reaction: An adverse reaction, the nature or severity of which is not consistent with the applicable product information.",
    "char_count": 150,
    "word_count": 22,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.60",
      "section_title": "Unexpected Adverse Drug Reaction: An adverse reaction, the nature or severity of which is not consistent with the applicable product information.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9ea33235e0fa",
    "chunk_index": 40,
    "text": "1.61 Vulnerable Subjects: Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.",
    "char_count": 301,
    "word_count": 45,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "1",
      "title": "Glossary",
      "version": "E6(R2)",
      "section_number": "1.61",
      "section_title": "Vulnerable Subjects: Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ead42d9b2fd2",
    "chunk_index": 0,
    "text": "2.1 Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).",
    "char_count": 215,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.1",
      "section_title": "Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_1b701bf86e3f",
    "chunk_index": 1,
    "text": "2.2 Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks.",
    "char_count": 259,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.2",
      "section_title": "Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_007d85ec8d98",
    "chunk_index": 2,
    "text": "2.3 The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society.",
    "char_count": 156,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.3",
      "section_title": "The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a21b51d32ffe",
    "chunk_index": 3,
    "text": "2.6 A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favourable opinion.",
    "char_count": 184,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.6",
      "section_title": "A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favourable opinion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bbdf899ba291",
    "chunk_index": 4,
    "text": "2.7 The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist.",
    "char_count": 187,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.7",
      "section_title": "The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5f6ef7cad8ed",
    "chunk_index": 5,
    "text": "2.8 Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s).",
    "char_count": 151,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.8",
      "section_title": "Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_45bd9d6094c9",
    "chunk_index": 6,
    "text": "2.10 All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.",
    "char_count": 153,
    "word_count": 22,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.10",
      "section_title": "All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_26622f596eea",
    "chunk_index": 7,
    "text": "2.11 The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).",
    "char_count": 195,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.11",
      "section_title": "The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3c8572627c48",
    "chunk_index": 8,
    "text": "2.12 Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol.",
    "char_count": 200,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.12",
      "section_title": "Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bbc2f7d6ddfe",
    "chunk_index": 9,
    "text": "2.14 ADDENDUM: Throughout the clinical trial, the sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and the applicable regulatory requirements.",
    "char_count": 336,
    "word_count": 47,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.14",
      "section_title": "ADDENDUM: Throughout the clinical trial, the sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and the applicable regulatory requirements.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7e0091d3aabf",
    "chunk_index": 10,
    "text": "2.15 ADDENDUM: Throughout the clinical trial, the sponsor should ensure appropriate safeguards are in place to protect the confidentiality of subject data in compliance with the applicable regulatory requirements.",
    "char_count": 213,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "2",
      "title": "The Principles of ICH GCP",
      "version": "E6(R2)",
      "section_number": "2.15",
      "section_title": "ADDENDUM: Throughout the clinical trial, the sponsor should ensure appropriate safeguards are in place to protect the confidentiality of subject data in compliance with the applicable regulatory requirements.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bc0293a5f5f1",
    "chunk_index": 0,
    "text": "3.1.1 An IRB/IEC should safeguard the rights, safety, and well-being of all trial subjects. Special attention should be paid to trials that may include vulnerable subjects.",
    "char_count": 172,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.1",
      "section_title": "An IRB/IEC should safeguard the rights, safety, and well-being of all trial subjects. Special attention should be paid to trials that may include vulnerable subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_27277acab97b",
    "chunk_index": 1,
    "text": "3.1.2 The IRB/IEC should obtain the following documents: trial protocol(s)/amendment(s), written informed consent form(s), consent form updates, subject recruitment procedures, written information to be provided to subjects, Investigator's Brochure (IB), available safety information, information about payments and compensation available to subjects, the investigator's current curriculum vitae and/or other documentation evidencing qualifications, and any other documents that the IRB/IEC may need to fulfil its responsibilities.",
    "char_count": 531,
    "word_count": 64,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.2",
      "section_title": "The IRB/IEC should obtain the following documents: trial protocol(s)/amendment(s), written informed consent form(s), consent form updates, subject recruitment procedures, written information to be provided to subjects, Investigator's Brochure (IB), available safety information, information about payments and compensation available to subjects, the investigator's current curriculum vitae and/or other documentation evidencing qualifications, and any other documents that the IRB/IEC may need to fulfil its responsibilities.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_03ceecc17960",
    "chunk_index": 2,
    "text": "3.1.3 The IRB/IEC should review a proposed clinical trial within a reasonable time and document its views in writing, clearly identifying the trial, the documents reviewed and the dates for approval, modifications required, disapproval, or termination.",
    "char_count": 252,
    "word_count": 36,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.3",
      "section_title": "The IRB/IEC should review a proposed clinical trial within a reasonable time and document its views in writing, clearly identifying the trial, the documents reviewed and the dates for approval, modifications required, disapproval, or termination.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e5f900c2e564",
    "chunk_index": 3,
    "text": "3.1.4 The IRB/IEC should consider the qualifications of the investigator for the proposed trial, as documented by a current curriculum vitae and/or by any other relevant documentation the IRB/IEC requests.",
    "char_count": 205,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.4",
      "section_title": "The IRB/IEC should consider the qualifications of the investigator for the proposed trial, as documented by a current curriculum vitae and/or by any other relevant documentation the IRB/IEC requests.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_143840daded0",
    "chunk_index": 4,
    "text": "3.1.5 The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to human subjects, but at least once per year.",
    "char_count": 166,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.5",
      "section_title": "The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to human subjects, but at least once per year.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c342348aecac",
    "chunk_index": 5,
    "text": "3.1.6 The IRB/IEC may request more information than is outlined in paragraph 3.1.2 be given to subjects when, in the judgement of the IRB/IEC, the additional information would add meaningfully to the protection of the rights, safety and/or well-being of the subjects.",
    "char_count": 267,
    "word_count": 42,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.6",
      "section_title": "The IRB/IEC may request more information than is outlined in paragraph 3.1.2 be given to subjects when, in the judgement of the IRB/IEC, the additional information would add meaningfully to the protection of the rights, safety and/or well-being of the subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2c7887620a62",
    "chunk_index": 6,
    "text": "3.1.7 When a non-therapeutic trial is to be carried out with the consent of the subject's legally acceptable representative, the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials.",
    "char_count": 314,
    "word_count": 43,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.7",
      "section_title": "When a non-therapeutic trial is to be carried out with the consent of the subject's legally acceptable representative, the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_abaa42a93e85",
    "chunk_index": 7,
    "text": "3.1.8 Where the protocol indicates that prior consent of the trial subject or the subject's legally acceptable representative is not possible, the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials.",
    "char_count": 332,
    "word_count": 45,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.8",
      "section_title": "Where the protocol indicates that prior consent of the trial subject or the subject's legally acceptable representative is not possible, the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7fe639e3b2b7",
    "chunk_index": 8,
    "text": "3.1.9 The IRB/IEC should review both the amount and method of payment to subjects to assure that neither presents problems of coercion or undue influence on the trial subjects.",
    "char_count": 176,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.1.9",
      "section_title": "The IRB/IEC should review both the amount and method of payment to subjects to assure that neither presents problems of coercion or undue influence on the trial subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_157aa6a2b45d",
    "chunk_index": 9,
    "text": "3.2.1 The IRB/IEC should consist of a reasonable number of members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial.",
    "char_count": 210,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.1",
      "section_title": "The IRB/IEC should consist of a reasonable number of members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7440976f0be0",
    "chunk_index": 10,
    "text": "3.2.2 The IRB/IEC should include at least one member whose primary area of interest is in a nonscientific area and at least one member who is independent of the institution/trial site.",
    "char_count": 184,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.2",
      "section_title": "The IRB/IEC should include at least one member whose primary area of interest is in a nonscientific area and at least one member who is independent of the institution/trial site.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d2c63ac88557",
    "chunk_index": 11,
    "text": "3.2.3 Only those IRB/IEC members who are independent of the investigator and the sponsor of the trial should vote/provide opinion on a trial-related matter.",
    "char_count": 156,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.3",
      "section_title": "Only those IRB/IEC members who are independent of the investigator and the sponsor of the trial should vote/provide opinion on a trial-related matter.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9840c449879a",
    "chunk_index": 12,
    "text": "3.2.4 The IRB/IEC should perform its functions according to written operating procedures, maintain written records of its activities and minutes of its meetings, and comply with GCP and with the applicable regulatory requirement(s).",
    "char_count": 232,
    "word_count": 33,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.4",
      "section_title": "The IRB/IEC should perform its functions according to written operating procedures, maintain written records of its activities and minutes of its meetings, and comply with GCP and with the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_97a04fae7c09",
    "chunk_index": 13,
    "text": "3.2.5 An IRB/IEC should make its decisions at announced meetings at which at least a quorum, as stipulated in its written operating procedures, is present.",
    "char_count": 155,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.5",
      "section_title": "An IRB/IEC should make its decisions at announced meetings at which at least a quorum, as stipulated in its written operating procedures, is present.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fcc50c2ff848",
    "chunk_index": 14,
    "text": "3.2.7 The investigator may provide information on any aspect of the trial, but should not participate in the deliberations of the IRB/IEC or in the vote/opinion of the IRB/IEC.",
    "char_count": 176,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "3",
      "title": "Institutional Review Board/Independent Ethics Committee (IRB/IEC)",
      "version": "E6(R2)",
      "section_number": "3.2.7",
      "section_title": "The investigator may provide information on any aspect of the trial, but should not participate in the deliberations of the IRB/IEC or in the vote/opinion of the IRB/IEC.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_988c32d07e30",
    "chunk_index": 0,
    "text": "4.1.2 The investigator should be thoroughly familiar with the appropriate use of the investigational product(s), as described in the protocol, in the current Investigator's Brochure, in the product information and in other information sources provided by the sponsor.",
    "char_count": 267,
    "word_count": 38,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.1.2",
      "section_title": "The investigator should be thoroughly familiar with the appropriate use of the investigational product(s), as described in the protocol, in the current Investigator's Brochure, in the product information and in other information sources provided by the sponsor.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2f4293f0873a",
    "chunk_index": 1,
    "text": "4.1.5 The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties.",
    "char_count": 153,
    "word_count": 20,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.1.5",
      "section_title": "The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_383fc8a6f9b9",
    "chunk_index": 2,
    "text": "4.2.1 The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable subjects within the agreed recruitment period.",
    "char_count": 194,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.2.1",
      "section_title": "The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable subjects within the agreed recruitment period.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_94c83b3047cb",
    "chunk_index": 3,
    "text": "4.2.4 The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions.",
    "char_count": 200,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.2.4",
      "section_title": "The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d3bc6219f17b",
    "chunk_index": 4,
    "text": "4.3.1 A qualified physician (or dentist, when appropriate), who is an investigator or a sub-investigator for the trial, should be responsible for all trial-related medical (or dental) decisions.",
    "char_count": 194,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.3.1",
      "section_title": "A qualified physician (or dentist, when appropriate), who is an investigator or a sub-investigator for the trial, should be responsible for all trial-related medical (or dental) decisions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_32633e06369b",
    "chunk_index": 5,
    "text": "4.3.2 During and following a subject's participation in a trial, the investigator/institution should ensure that adequate medical care is provided to a subject for any adverse events, including clinically significant laboratory values, related to the trial.",
    "char_count": 257,
    "word_count": 36,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.3.2",
      "section_title": "During and following a subject's participation in a trial, the investigator/institution should ensure that adequate medical care is provided to a subject for any adverse events, including clinically significant laboratory values, related to the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2090ff9d560d",
    "chunk_index": 6,
    "text": "4.3.4 It is recommended that the investigator inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed.",
    "char_count": 237,
    "word_count": 37,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.3.4",
      "section_title": "It is recommended that the investigator inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a7ac26e706c3",
    "chunk_index": 7,
    "text": "4.4.1 Before initiating a trial, the investigator/institution should have written and dated approval/favourable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures, and any other written information to be provided to subjects.",
    "char_count": 307,
    "word_count": 41,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.4.1",
      "section_title": "Before initiating a trial, the investigator/institution should have written and dated approval/favourable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures, and any other written information to be provided to subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_92c7225370f6",
    "chunk_index": 8,
    "text": "4.4.2 As part of the investigator's/institution's written application to the IRB/IEC, the investigator/institution should provide the IRB/IEC with a current copy of the Investigator's Brochure.",
    "char_count": 193,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.4.2",
      "section_title": "As part of the investigator's/institution's written application to the IRB/IEC, the investigator/institution should provide the IRB/IEC with a current copy of the Investigator's Brochure.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b1a431fd0f6c",
    "chunk_index": 9,
    "text": "4.5.1 The investigator/institution should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was given approval/favourable opinion by the IRB/IEC.",
    "char_count": 231,
    "word_count": 33,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.5.1",
      "section_title": "The investigator/institution should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was given approval/favourable opinion by the IRB/IEC.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_de3d10bf819b",
    "chunk_index": 10,
    "text": "4.5.2 The investigator should not implement any deviation from, or changes of the protocol without agreement by the sponsor and prior review and documented approval/favourable opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to trial subjects.",
    "char_count": 295,
    "word_count": 43,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.5.2",
      "section_title": "The investigator should not implement any deviation from, or changes of the protocol without agreement by the sponsor and prior review and documented approval/favourable opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to trial subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_dd7c7374808e",
    "chunk_index": 11,
    "text": "4.5.4 The investigator may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC approval/favourable opinion.",
    "char_count": 188,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.5.4",
      "section_title": "The investigator may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC approval/favourable opinion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9b77a8b84fc9",
    "chunk_index": 12,
    "text": "4.6.2 Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institution's duties for investigational product(s) accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution.",
    "char_count": 323,
    "word_count": 38,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.6.2",
      "section_title": "Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institution's duties for investigational product(s) accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a13012f58c40",
    "chunk_index": 13,
    "text": "4.6.3 The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s).",
    "char_count": 338,
    "word_count": 49,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.6.3",
      "section_title": "The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ce92fc6c969a",
    "chunk_index": 14,
    "text": "4.6.6 The investigator, or a person designated by the investigator/institution, should explain the correct use of the investigational product(s) to each subject and should check, at intervals appropriate for the trial, that each subject is following the instructions properly.",
    "char_count": 276,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.6.6",
      "section_title": "The investigator, or a person designated by the investigator/institution, should explain the correct use of the investigational product(s) to each subject and should check, at intervals appropriate for the trial, that each subject is following the instructions properly.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5d2c7120ba71",
    "chunk_index": 15,
    "text": "4.7 Randomization Procedures and Unblinding\nThe investigator should follow the trial's randomization procedures, if any, and should ensure that the code is broken only in accordance with the protocol.",
    "char_count": 200,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.7",
      "section_title": "Randomization Procedures and Unblinding",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7ec9d0407e86",
    "chunk_index": 16,
    "text": "4.8.1 In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki.",
    "char_count": 240,
    "word_count": 35,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.1",
      "section_title": "In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_89a94d8b8f42",
    "chunk_index": 17,
    "text": "4.8.2 Before informed consent may be obtained, the investigator, or a person designated by the investigator, should provide the subject or the subject's legally acceptable representative ample time and opportunity to inquire about details of the trial and to decide whether or not to participate in the trial.",
    "char_count": 309,
    "word_count": 48,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.2",
      "section_title": "Before informed consent may be obtained, the investigator, or a person designated by the investigator, should provide the subject or the subject's legally acceptable representative ample time and opportunity to inquire about details of the trial and to decide whether or not to participate in the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f0220664f38b",
    "chunk_index": 18,
    "text": "4.8.3 Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial.",
    "char_count": 153,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.3",
      "section_title": "Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_16d4f9e422ec",
    "chunk_index": 19,
    "text": "4.8.4 None of the oral and written information concerning the trial, including the written informed consent form, should contain any language that causes the subject or the subject's legally acceptable representative to waive or to appear to waive any legal rights.",
    "char_count": 265,
    "word_count": 41,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.4",
      "section_title": "None of the oral and written information concerning the trial, including the written informed consent form, should contain any language that causes the subject or the subject's legally acceptable representative to waive or to appear to waive any legal rights.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_736330b84ef6",
    "chunk_index": 20,
    "text": "4.8.5 The investigator, or a person designated by the investigator, should fully inform the subject or, if the subject is unable to provide informed consent, the subject's legally acceptable representative, of all pertinent aspects of the trial.",
    "char_count": 245,
    "word_count": 37,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.5",
      "section_title": "The investigator, or a person designated by the investigator, should fully inform the subject or, if the subject is unable to provide informed consent, the subject's legally acceptable representative, of all pertinent aspects of the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_630faa84ad2d",
    "chunk_index": 21,
    "text": "4.8.6 The language used in the oral and written information about the trial, including the written informed consent form, should be as non-technical as practical.",
    "char_count": 162,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.6",
      "section_title": "The language used in the oral and written information about the trial, including the written informed consent form, should be as non-technical as practical.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_630c930819a2",
    "chunk_index": 22,
    "text": "4.8.7 If the subject or the subject's legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion.",
    "char_count": 176,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.7",
      "section_title": "If the subject or the subject's legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_06d3057ef79a",
    "chunk_index": 23,
    "text": "4.8.8 Before a subject's participation in the trial, the written informed consent form should be signed and personally dated by the subject or by the subject's legally acceptable representative, and by the person who conducted the informed consent discussion.",
    "char_count": 259,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.8",
      "section_title": "Before a subject's participation in the trial, the written informed consent form should be signed and personally dated by the subject or by the subject's legally acceptable representative, and by the person who conducted the informed consent discussion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f5cddf58444a",
    "chunk_index": 24,
    "text": "4.8.9 If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion.",
    "char_count": 183,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.9",
      "section_title": "If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e822149e7605",
    "chunk_index": 25,
    "text": "4.8.10 Both the informed consent discussion and the written informed consent form and any other written information to be provided to subjects should include explanations of the nature and purpose of the trial, trial treatment(s), probability of random assignment, trial procedures, subject's responsibilities, the reasonably foreseeable risks, the expected benefits, alternative procedures or treatments, compensation, confidentiality provisions, voluntary participation, and whom to contact for trial-related questions.",
    "char_count": 521,
    "word_count": 66,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.8.10",
      "section_title": "Both the informed consent discussion and the written informed consent form and any other written information to be provided to subjects should include explanations of the nature and purpose of the trial, trial treatment(s), probability of random assignment, trial procedures, subject's responsibilities, the reasonably foreseeable risks, the expected benefits, alternative procedures or treatments, compensation, confidentiality provisions, voluntary participation, and whom to contact for trial-related questions.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_62b7451accf1",
    "chunk_index": 26,
    "text": "4.9.1 The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs and in all required reports.",
    "char_count": 168,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.9.1",
      "section_title": "The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs and in all required reports.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_1c83bf9b6431",
    "chunk_index": 27,
    "text": "4.9.2 Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained.",
    "char_count": 160,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.9.2",
      "section_title": "Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4fd1dbaad9c1",
    "chunk_index": 28,
    "text": "4.9.4 The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial and as required by the applicable regulatory requirement(s).",
    "char_count": 203,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.9.4",
      "section_title": "The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial and as required by the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_848e7f30341b",
    "chunk_index": 29,
    "text": "4.9.5 Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product.",
    "char_count": 344,
    "word_count": 55,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.9.5",
      "section_title": "Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_aa6ff947b325",
    "chunk_index": 30,
    "text": "4.9.7 Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution should make available for direct access all requested trial-related records.",
    "char_count": 183,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.9.7",
      "section_title": "Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution should make available for direct access all requested trial-related records.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3e8b0bb78540",
    "chunk_index": 31,
    "text": "4.10.2 The investigator should promptly provide written reports to the sponsor, the IRB/IEC, and, where applicable, the institution on any changes significantly affecting the conduct of the trial, and/or increasing the risk to subjects.",
    "char_count": 236,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.10.2",
      "section_title": "The investigator should promptly provide written reports to the sponsor, the IRB/IEC, and, where applicable, the institution on any changes significantly affecting the conduct of the trial, and/or increasing the risk to subjects.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_922f4c1ffbb5",
    "chunk_index": 32,
    "text": "4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting.",
    "char_count": 223,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.11.1",
      "section_title": "All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e49f28ee8a3b",
    "chunk_index": 33,
    "text": "4.11.2 The investigator should comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.",
    "char_count": 203,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.11.2",
      "section_title": "The investigator should comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3a5166582ed7",
    "chunk_index": 34,
    "text": "4.11.3 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.",
    "char_count": 258,
    "word_count": 38,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.11.3",
      "section_title": "Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d1ec244e3c55",
    "chunk_index": 35,
    "text": "4.12 Premature Termination or Suspension of a Trial\nIf the trial is prematurely terminated or suspended for any reason, the investigator/institution should promptly inform the trial subjects, should assure appropriate therapy and follow-up for the subjects, and, where required by the applicable regulatory requirement(s), should inform the regulatory authority(ies).",
    "char_count": 367,
    "word_count": 49,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.12",
      "section_title": "Premature Termination or Suspension of a Trial",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3915177cdef9",
    "chunk_index": 36,
    "text": "4.13 Final Report(s) by Investigator\nUpon completion of the trial, the investigator, where applicable, should inform the institution; the investigator/institution should provide the IRB/IEC with a summary of the trial's outcome, and the regulatory authority(ies) with any reports required.",
    "char_count": 289,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "4",
      "title": "Investigator",
      "version": "E6(R2)",
      "section_number": "4.13",
      "section_title": "Final Report(s) by Investigator",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_94871c27d7e1",
    "chunk_index": 0,
    "text": "5.0.3 Quality management includes the design of trial protocols and tools and procedures for the collection and processing of information, as well as the collection of information that is essential to decision making.",
    "char_count": 217,
    "word_count": 33,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.0.3",
      "section_title": "Quality management includes the design of trial protocols and tools and procedures for the collection and processing of information, as well as the collection of information that is essential to decision making.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e74d2c3a12bb",
    "chunk_index": 1,
    "text": "5.0.4 The methods used to assure and control the quality of the trial should be proportionate to the risks inherent in the trial and the importance of the information collected.",
    "char_count": 177,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.0.4",
      "section_title": "The methods used to assure and control the quality of the trial should be proportionate to the risks inherent in the trial and the importance of the information collected.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bb61868d2078",
    "chunk_index": 2,
    "text": "5.0.5 The sponsor should ensure that each individual involved in the trial is qualified by education, training, and experience to perform the respective task(s).",
    "char_count": 161,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.0.5",
      "section_title": "The sponsor should ensure that each individual involved in the trial is qualified by education, training, and experience to perform the respective task(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9b2ce45aa138",
    "chunk_index": 3,
    "text": "5.1.1 The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s).",
    "char_count": 309,
    "word_count": 43,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.1.1",
      "section_title": "The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c7d7c3dcd83e",
    "chunk_index": 4,
    "text": "5.1.2 The sponsor is responsible for securing agreement from all involved parties to ensure direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities.",
    "char_count": 290,
    "word_count": 43,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.1.2",
      "section_title": "The sponsor is responsible for securing agreement from all involved parties to ensure direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2f453f7ba130",
    "chunk_index": 5,
    "text": "5.1.4 Agreements, made by the sponsor with the investigator/institution and any other parties involved with the clinical trial, should be in writing, as part of the protocol or in a separate agreement.",
    "char_count": 201,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.1.4",
      "section_title": "Agreements, made by the sponsor with the investigator/institution and any other parties involved with the clinical trial, should be in writing, as part of the protocol or in a separate agreement.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8b23a15fdaa5",
    "chunk_index": 6,
    "text": "5.2.1 A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor.",
    "char_count": 214,
    "word_count": 36,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.2.1",
      "section_title": "A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bff406b5ab86",
    "chunk_index": 7,
    "text": "5.2.4 All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial related duties and functions of a sponsor.",
    "char_count": 161,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.2.4",
      "section_title": "All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial related duties and functions of a sponsor.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fec4ba1470f3",
    "chunk_index": 8,
    "text": "5.3 Medical Expertise\nThe sponsor should designate appropriately qualified medical personnel who will be readily available to advise on trial related medical questions or problems.",
    "char_count": 180,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.3",
      "section_title": "Medical Expertise",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_6d17e9892141",
    "chunk_index": 9,
    "text": "5.4.1 The sponsor should utilize qualified individuals (e.g., biostatisticians, clinical pharmacologists, and physicians) as appropriate, throughout all stages of the trial process.",
    "char_count": 181,
    "word_count": 22,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.4.1",
      "section_title": "The sponsor should utilize qualified individuals (e.g., biostatisticians, clinical pharmacologists, and physicians) as appropriate, throughout all stages of the trial process.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_15af6bbb2e39",
    "chunk_index": 10,
    "text": "5.5.1 The sponsor should utilize appropriately qualified individuals to supervise the overall conduct of the trial, to handle the data, to verify the data, to conduct the statistical analyses, and to prepare the trial reports.",
    "char_count": 226,
    "word_count": 35,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.1",
      "section_title": "The sponsor should utilize appropriately qualified individuals to supervise the overall conduct of the trial, to handle the data, to verify the data, to conduct the statistical analyses, and to prepare the trial reports.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d7658a076b15",
    "chunk_index": 11,
    "text": "5.5.3 When using electronic trial data handling and/or remote electronic trial data systems, the sponsor should ensure and document that the electronic data processing system(s) conforms to the sponsor's established requirements for completeness, accuracy, reliability, and consistent intended performance.",
    "char_count": 306,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.3",
      "section_title": "When using electronic trial data handling and/or remote electronic trial data systems, the sponsor should ensure and document that the electronic data processing system(s) conforms to the sponsor's established requirements for completeness, accuracy, reliability, and consistent intended performance.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_20b17ef71d1b",
    "chunk_index": 12,
    "text": "5.5.6 The sponsor should retain all sponsor-specific essential documents in conformance with the applicable regulatory requirement(s) of the country(ies) where the product is approved.",
    "char_count": 184,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.6",
      "section_title": "The sponsor should retain all sponsor-specific essential documents in conformance with the applicable regulatory requirement(s) of the country(ies) where the product is approved.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f0625dc383b3",
    "chunk_index": 13,
    "text": "5.5.7 If the sponsor discontinues the clinical development of an investigational product, the sponsor should maintain all sponsor-specific essential documents for at least 2 years after formal discontinuation.",
    "char_count": 209,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.7",
      "section_title": "If the sponsor discontinues the clinical development of an investigational product, the sponsor should maintain all sponsor-specific essential documents for at least 2 years after formal discontinuation.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2d71b18d465b",
    "chunk_index": 14,
    "text": "5.5.8 If the sponsor discontinues the clinical development of an investigational product, the sponsor should notify all the trial investigators/institutions and all the regulatory authorities.",
    "char_count": 192,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.8",
      "section_title": "If the sponsor discontinues the clinical development of an investigational product, the sponsor should notify all the trial investigators/institutions and all the regulatory authorities.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_42537970c204",
    "chunk_index": 15,
    "text": "5.5.10 The sponsor specific essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region.",
    "char_count": 158,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.10",
      "section_title": "The sponsor specific essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e16b53ba4c2e",
    "chunk_index": 16,
    "text": "5.5.12 The sponsor should inform the investigator(s)/institution(s) in writing of the need for record retention and should notify the investigator(s)/institution(s) in writing when the trial related records are no longer needed.",
    "char_count": 228,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.5.12",
      "section_title": "The sponsor should inform the investigator(s)/institution(s) in writing of the need for record retention and should notify the investigator(s)/institution(s) in writing when the trial related records are no longer needed.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9f846314deb4",
    "chunk_index": 17,
    "text": "5.6.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by training and experience and should have adequate resources to properly conduct the trial.",
    "char_count": 213,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.6.1",
      "section_title": "The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by training and experience and should have adequate resources to properly conduct the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_dce4cad0af88",
    "chunk_index": 18,
    "text": "5.6.2 Before entering an agreement with an investigator/institution to conduct a trial, the sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-date Investigator's Brochure.",
    "char_count": 210,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.6.2",
      "section_title": "Before entering an agreement with an investigator/institution to conduct a trial, the sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-date Investigator's Brochure.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bef0f9453725",
    "chunk_index": 19,
    "text": "5.6.3 The sponsor should obtain the investigator's/institution's agreement to conduct the trial in compliance with GCP, to comply with procedures for data recording and reporting, and to permit monitoring, auditing, and inspection.",
    "char_count": 231,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.6.3",
      "section_title": "The sponsor should obtain the investigator's/institution's agreement to conduct the trial in compliance with GCP, to comply with procedures for data recording and reporting, and to permit monitoring, auditing, and inspection.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b619f1ba46ab",
    "chunk_index": 20,
    "text": "5.7 Allocation of Duties and Functions\nPrior to initiating a trial, the sponsor should define, establish, and allocate all trial-related duties and functions.",
    "char_count": 158,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.7",
      "section_title": "Allocation of Duties and Functions",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0c5f6d94582d",
    "chunk_index": 21,
    "text": "5.8.1 If required by the applicable regulatory requirement(s), the sponsor should provide insurance or should indemnify the investigator/the institution against claims arising from the trial.",
    "char_count": 191,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.8.1",
      "section_title": "If required by the applicable regulatory requirement(s), the sponsor should provide insurance or should indemnify the investigator/the institution against claims arising from the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7ff2c3146019",
    "chunk_index": 22,
    "text": "5.8.3 When trial subjects receive compensation, the method and manner of compensation should be in compliance with applicable regulatory requirement(s).",
    "char_count": 152,
    "word_count": 20,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.8.3",
      "section_title": "When trial subjects receive compensation, the method and manner of compensation should be in compliance with applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5aaa3847b6ed",
    "chunk_index": 23,
    "text": "5.10 Notification/Submission to Regulatory Authority(ies)\nBefore initiating the clinical trial(s), the sponsor (or the sponsor and the investigator, if required by the applicable regulatory requirement(s)) should submit any required application(s) to the appropriate authority(ies) for review, acceptance, and/or permission (as required by the applicable regulatory requirement(s)) to begin the trial(s).",
    "char_count": 404,
    "word_count": 50,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.10",
      "section_title": "Notification/Submission to Regulatory Authority(ies)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5d4e4d195e1a",
    "chunk_index": 24,
    "text": "5.11.2 If the IRB/IEC conditions its approval/favourable opinion upon change(s) in any aspect of the trial, such as modification(s) of the protocol, written informed consent form and any other written information to be provided to subjects, and/or other procedures, the sponsor should obtain from the investigator/institution a copy of the modification(s) made and the date approval/favourable opinion was given by the IRB/IEC.",
    "char_count": 427,
    "word_count": 62,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.11.2",
      "section_title": "If the IRB/IEC conditions its approval/favourable opinion upon change(s) in any aspect of the trial, such as modification(s) of the protocol, written informed consent form and any other written information to be provided to subjects, and/or other procedures, the sponsor should obtain from the investigator/institution a copy of the modification(s) made and the date approval/favourable opinion was given by the IRB/IEC.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e3d8df3d3036",
    "chunk_index": 25,
    "text": "5.11.3 The sponsor should obtain from the investigator/institution documentation and dates of any IRB/IEC re-approvals/re-evaluations with favourable opinion, and of any withdrawals or suspensions of approval/favourable opinion.",
    "char_count": 228,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.11.3",
      "section_title": "The sponsor should obtain from the investigator/institution documentation and dates of any IRB/IEC re-approvals/re-evaluations with favourable opinion, and of any withdrawals or suspensions of approval/favourable opinion.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f7c9e9c3c37a",
    "chunk_index": 26,
    "text": "5.12.1 When planning trials, the sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.",
    "char_count": 274,
    "word_count": 43,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.12.1",
      "section_title": "When planning trials, the sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e336c3f7df0c",
    "chunk_index": 27,
    "text": "5.13.1 The sponsor should ensure that the investigational product(s) (including active comparator(s) and placebo, if applicable) is characterized as appropriate to the stage of development of the product(s), is manufactured in accordance with any applicable GMP, and is coded and labelled in a manner that protects the blinding, if applicable.",
    "char_count": 343,
    "word_count": 50,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.13.1",
      "section_title": "The sponsor should ensure that the investigational product(s) (including active comparator(s) and placebo, if applicable) is characterized as appropriate to the stage of development of the product(s), is manufactured in accordance with any applicable GMP, and is coded and labelled in a manner that protects the blinding, if applicable.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0493ce01df7a",
    "chunk_index": 28,
    "text": "5.13.2 The sponsor should determine, for the investigational product(s), acceptable storage temperatures, storage conditions, storage times, reconstitution fluids and procedures, and devices for product infusion, if any.",
    "char_count": 220,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.13.2",
      "section_title": "The sponsor should determine, for the investigational product(s), acceptable storage temperatures, storage conditions, storage times, reconstitution fluids and procedures, and devices for product infusion, if any.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_62bd43785b50",
    "chunk_index": 29,
    "text": "5.13.4 In blinded trials, the coding system for the investigational product(s) should include a mechanism that permits rapid identification of the product(s) in case of a medical emergency, but does not permit undetectable breaks of the blinding.",
    "char_count": 246,
    "word_count": 37,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.13.4",
      "section_title": "In blinded trials, the coding system for the investigational product(s) should include a mechanism that permits rapid identification of the product(s) in case of a medical emergency, but does not permit undetectable breaks of the blinding.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_67c63a4122a7",
    "chunk_index": 30,
    "text": "5.13.5 If significant formulation changes are made in the investigational or comparator product(s) during the course of clinical development, the results of any additional studies of the formulated product(s) (e.g., stability, dissolution rate, bioavailability) needed to assess whether these changes would significantly alter the pharmacokinetic profile of the product should be available prior to the use of the new formulation in clinical trials.",
    "char_count": 449,
    "word_count": 63,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.13.5",
      "section_title": "If significant formulation changes are made in the investigational or comparator product(s) during the course of clinical development, the results of any additional studies of the formulated product(s) (e.g., stability, dissolution rate, bioavailability) needed to assess whether these changes would significantly alter the pharmacokinetic profile of the product should be available prior to the use of the new formulation in clinical trials.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_03585b52b156",
    "chunk_index": 31,
    "text": "5.14.2 The sponsor should not supply an investigator/institution with the investigational product(s) until the sponsor obtains all required documentation.",
    "char_count": 154,
    "word_count": 19,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.14.2",
      "section_title": "The sponsor should not supply an investigator/institution with the investigational product(s) until the sponsor obtains all required documentation.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d192e815aadf",
    "chunk_index": 32,
    "text": "5.14.3 The sponsor should ensure that written procedures include instructions that the investigator/institution should follow for the handling and storage of investigational product(s) for the trial and documentation thereof.",
    "char_count": 225,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.14.3",
      "section_title": "The sponsor should ensure that written procedures include instructions that the investigator/institution should follow for the handling and storage of investigational product(s) for the trial and documentation thereof.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_209e337338a6",
    "chunk_index": 33,
    "text": "5.14.4 The sponsor should maintain sufficient quantities of the investigational product(s) used in the trials to reconfirm specifications, should the need arise, and maintain records of batch sample analyses and characteristics.",
    "char_count": 228,
    "word_count": 31,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.14.4",
      "section_title": "The sponsor should maintain sufficient quantities of the investigational product(s) used in the trials to reconfirm specifications, should the need arise, and maintain records of batch sample analyses and characteristics.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_116b6b769ce2",
    "chunk_index": 34,
    "text": "5.15.1 The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) provide direct access to source data/documents for trial-related monitoring, audits, IRB/IEC review, and regulatory inspection.",
    "char_count": 264,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.15.1",
      "section_title": "The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) provide direct access to source data/documents for trial-related monitoring, audits, IRB/IEC review, and regulatory inspection.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_50b380b9f4f5",
    "chunk_index": 35,
    "text": "5.15.2 The sponsor should verify that each subject has consented, in writing, to direct access to his/her original medical records for trial-related monitoring, audit, IRB/IEC review, and regulatory inspection.",
    "char_count": 210,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.15.2",
      "section_title": "The sponsor should verify that each subject has consented, in writing, to direct access to his/her original medical records for trial-related monitoring, audit, IRB/IEC review, and regulatory inspection.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_233210348c26",
    "chunk_index": 36,
    "text": "5.16.2 The sponsor should promptly notify all concerned investigator(s)/institution(s) and the regulatory authority(ies) of findings that could affect adversely the safety of subjects, impact the conduct of the trial, or alter the IRB's/IEC's approval/favourable opinion to continue the trial.",
    "char_count": 293,
    "word_count": 39,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.16.2",
      "section_title": "The sponsor should promptly notify all concerned investigator(s)/institution(s) and the regulatory authority(ies) of findings that could affect adversely the safety of subjects, impact the conduct of the trial, or alter the IRB's/IEC's approval/favourable opinion to continue the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_06c6b31160b8",
    "chunk_index": 37,
    "text": "5.17.1 The sponsor should expedite the reporting to all concerned investigator(s)/institutions(s), to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse drug reactions (ADRs) that are both serious and unexpected.",
    "char_count": 248,
    "word_count": 33,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.17.1",
      "section_title": "The sponsor should expedite the reporting to all concerned investigator(s)/institutions(s), to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse drug reactions (ADRs) that are both serious and unexpected.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9235bb96d3a9",
    "chunk_index": 38,
    "text": "5.17.2 Such expedited reports should comply with the applicable regulatory requirement(s) and with the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.",
    "char_count": 204,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.17.2",
      "section_title": "Such expedited reports should comply with the applicable regulatory requirement(s) and with the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_18db458d0546",
    "chunk_index": 39,
    "text": "5.17.3 The sponsor should submit to the regulatory authority(ies) all safety updates and periodic reports, as required by applicable regulatory requirement(s).",
    "char_count": 159,
    "word_count": 21,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.17.3",
      "section_title": "The sponsor should submit to the regulatory authority(ies) all safety updates and periodic reports, as required by applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8a8a1acb15a8",
    "chunk_index": 40,
    "text": "5.18.1 Purpose: The purposes of trial monitoring are to verify that the rights and well-being of human subjects are protected, that the reported trial data are accurate, complete, and verifiable from source documents, and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirement(s).",
    "char_count": 380,
    "word_count": 56,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.18.1",
      "section_title": "Purpose: The purposes of trial monitoring are to verify that the rights and well-being of human subjects are protected, that the reported trial data are accurate, complete, and verifiable from source documents, and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirement(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e4a0f549369a",
    "chunk_index": 41,
    "text": "5.18.2 Selection and Qualifications of Monitors: Monitors should be appointed by the sponsor and should be appropriately trained, and should have the scientific and/or clinical knowledge needed to monitor the trial adequately.",
    "char_count": 226,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.18.2",
      "section_title": "Selection and Qualifications of Monitors: Monitors should be appointed by the sponsor and should be appropriately trained, and should have the scientific and/or clinical knowledge needed to monitor the trial adequately.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4b33786c0661",
    "chunk_index": 42,
    "text": "5.18.3 Extent of Monitoring: The sponsor should ensure that the trials are adequately monitored. The sponsor should determine the appropriate extent and nature of monitoring.",
    "char_count": 174,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.18.3",
      "section_title": "Extent of Monitoring: The sponsor should ensure that the trials are adequately monitored. The sponsor should determine the appropriate extent and nature of monitoring.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_df63d36fa432",
    "chunk_index": 43,
    "text": "5.18.4 Monitor's Responsibilities: The monitor(s) in accordance with the sponsor's requirements should ensure that the trial is conducted and documented properly.",
    "char_count": 162,
    "word_count": 21,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.18.4",
      "section_title": "Monitor's Responsibilities: The monitor(s) in accordance with the sponsor's requirements should ensure that the trial is conducted and documented properly.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_f00a2cb98026",
    "chunk_index": 44,
    "text": "5.18.5 Monitoring Procedures: The monitor(s) should follow the sponsor's established written SOPs as well as those procedures that are specified by the sponsor for monitoring a specific trial.",
    "char_count": 192,
    "word_count": 28,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.18.5",
      "section_title": "Monitoring Procedures: The monitor(s) should follow the sponsor's established written SOPs as well as those procedures that are specified by the sponsor for monitoring a specific trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fb4180469e9b",
    "chunk_index": 45,
    "text": "5.19 Audit\nIf or when sponsors perform audits, as part of implementing quality assurance, they should consider the purpose of an audit, the independence and qualifications of the auditors, procedures for auditing, reporting, and follow-up.",
    "char_count": 239,
    "word_count": 35,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.19",
      "section_title": "Audit",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2837de5ae1c3",
    "chunk_index": 46,
    "text": "5.20.1 Noncompliance with the protocol, SOPs, GCP, and/or applicable regulatory requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff should lead to prompt action by the sponsor to secure compliance.",
    "char_count": 231,
    "word_count": 32,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.20.1",
      "section_title": "Noncompliance with the protocol, SOPs, GCP, and/or applicable regulatory requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff should lead to prompt action by the sponsor to secure compliance.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_13420ea95fd2",
    "chunk_index": 47,
    "text": "5.20.2 If the monitoring and/or auditing identifies serious and/or persistent noncompliance on the part of an investigator/institution, the sponsor should terminate the investigator's/institution's participation in the trial.",
    "char_count": 225,
    "word_count": 27,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.20.2",
      "section_title": "If the monitoring and/or auditing identifies serious and/or persistent noncompliance on the part of an investigator/institution, the sponsor should terminate the investigator's/institution's participation in the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_6c8e964031a1",
    "chunk_index": 48,
    "text": "5.20.3 When an investigator's/institution's participation is terminated because of noncompliance, the sponsor should notify promptly the regulatory authority(ies).",
    "char_count": 163,
    "word_count": 18,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.20.3",
      "section_title": "When an investigator's/institution's participation is terminated because of noncompliance, the sponsor should notify promptly the regulatory authority(ies).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_066dbb11c0e9",
    "chunk_index": 49,
    "text": "5.21 Premature Termination or Suspension of a Trial\nIf a trial is prematurely terminated or suspended, the sponsor should promptly inform the investigators/institutions, and the regulatory authority(ies) of the termination or suspension and the reason(s) for the termination or suspension.",
    "char_count": 289,
    "word_count": 40,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.21",
      "section_title": "Premature Termination or Suspension of a Trial",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fbc3e8f5aa4f",
    "chunk_index": 50,
    "text": "5.22 Clinical Trial/Study Reports\nWhether the trial is completed or prematurely terminated, the sponsor should ensure that the clinical trial reports are prepared and provided to the regulatory agency(ies) as required by the applicable regulatory requirement(s).",
    "char_count": 262,
    "word_count": 36,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.22",
      "section_title": "Clinical Trial/Study Reports",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5bbd4ba72210",
    "chunk_index": 51,
    "text": "5.23 Multicentre Trials\nFor multicentre trials, the sponsor should ensure that all investigators conduct the trial in strict compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies), and given approval/favourable opinion by the IRB/IEC.",
    "char_count": 284,
    "word_count": 41,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "5",
      "title": "Sponsor",
      "version": "E6(R2)",
      "section_number": "5.23",
      "section_title": "Multicentre Trials",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_11c630f56a53",
    "chunk_index": 0,
    "text": "The contents of a trial protocol should generally include the following topics. However, site specific information may be provided on separate protocol page(s), or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigator's Brochure.",
    "char_count": 332,
    "word_count": 49,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_91f59d19f85b",
    "chunk_index": 1,
    "text": "6.1.5 Name and title of the investigator(s) who is (are) responsible for conducting the trial, and the address and telephone number(s) of the trial site(s).",
    "char_count": 156,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.1.5",
      "section_title": "Name and title of the investigator(s) who is (are) responsible for conducting the trial, and the address and telephone number(s) of the trial site(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7a4e6388eb88",
    "chunk_index": 2,
    "text": "6.1.6 Name, title, address, and telephone number(s) of the qualified physician (or dentist, if applicable), who is responsible for all trial-site related medical (or dental) decisions (if other than investigator).",
    "char_count": 213,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.1.6",
      "section_title": "Name, title, address, and telephone number(s) of the qualified physician (or dentist, if applicable), who is responsible for all trial-site related medical (or dental) decisions (if other than investigator).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8aa87692cdd1",
    "chunk_index": 3,
    "text": "6.1.7 Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical department(s) and/or institutions involved in the trial.",
    "char_count": 153,
    "word_count": 20,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.1.7",
      "section_title": "Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical department(s) and/or institutions involved in the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a5c6be4acd42",
    "chunk_index": 4,
    "text": "6.2.2 A summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial.",
    "char_count": 153,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.2.2",
      "section_title": "A summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_53a1fee09922",
    "chunk_index": 5,
    "text": "6.4.2 A description of the type/design of trial to be conducted (e.g., double-blind, placebo-controlled, parallel design) and a schematic diagram of trial design, procedures and stages.",
    "char_count": 185,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.4.2",
      "section_title": "A description of the type/design of trial to be conducted (e.g., double-blind, placebo-controlled, parallel design) and a schematic diagram of trial design, procedures and stages.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bb2e9a06a30e",
    "chunk_index": 6,
    "text": "6.4.5 The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up, if any.",
    "char_count": 151,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.4.5",
      "section_title": "The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up, if any.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8f8c2d128e3d",
    "chunk_index": 7,
    "text": "6.4.9 The identification of any data to be recorded directly on the CRFs (i.e., no prior written or electronic record of data), and to be considered to be source data.",
    "char_count": 167,
    "word_count": 30,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.4.9",
      "section_title": "The identification of any data to be recorded directly on the CRFs (i.e., no prior written or electronic record of data), and to be considered to be source data.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_038533a4bfdd",
    "chunk_index": 8,
    "text": "6.5.3 Subject withdrawal criteria (i.e., terminating investigational product treatment/trial treatment) and procedures specifying when and how to withdraw subjects from the trial/investigational product treatment.",
    "char_count": 213,
    "word_count": 24,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.5.3",
      "section_title": "Subject withdrawal criteria (i.e., terminating investigational product treatment/trial treatment) and procedures specifying when and how to withdraw subjects from the trial/investigational product treatment.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2206069acec5",
    "chunk_index": 9,
    "text": "6.6.1 The treatment(s) to be administered, including the name(s) of all the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the treatment period(s).",
    "char_count": 190,
    "word_count": 26,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.6.1",
      "section_title": "The treatment(s) to be administered, including the name(s) of all the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the treatment period(s).",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_6eff117116ed",
    "chunk_index": 10,
    "text": "6.9.2 The number of subjects planned to be enrolled. In multicentre trials, the numbers of enrolled subjects projected for each trial site should be specified.",
    "char_count": 159,
    "word_count": 25,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.9.2",
      "section_title": "The number of subjects planned to be enrolled. In multicentre trials, the numbers of enrolled subjects projected for each trial site should be specified.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_81895eb5aad0",
    "chunk_index": 11,
    "text": "6.10 Direct Access to Source Data/Documents\nThe sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, and regulatory inspection(s), providing direct access to source data/documents.",
    "char_count": 315,
    "word_count": 40,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.10",
      "section_title": "Direct Access to Source Data/Documents",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_932718b860f5",
    "chunk_index": 12,
    "text": "6.16 Supplements\nProtocol supplements are listed as follows:\n- Protocol signature page\n- Amendments\n- Administrative pages\n- Appendices and attachments",
    "char_count": 151,
    "word_count": 21,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "6",
      "title": "Clinical Trial Protocol and Protocol Amendment(s)",
      "version": "E6(R2)",
      "section_number": "6.16",
      "section_title": "Supplements",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9b81332c0eee",
    "chunk_index": 0,
    "text": "7.1 Introduction\nThe Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects.\n\nIts purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol.\n\nThe IB also provides insight to support the clinical management of the study subjects during the course of the clinical trial.",
    "char_count": 550,
    "word_count": 86,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "7",
      "title": "Investigator's Brochure",
      "version": "E6(R2)",
      "section_number": "7.1",
      "section_title": "Introduction",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7115ea81e09a",
    "chunk_index": 1,
    "text": "7.2.1 The IB should include a summary of the relevant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic, and clinical information available that is relevant to the stage of clinical development of the investigational product.",
    "char_count": 270,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "7",
      "title": "Investigator's Brochure",
      "version": "E6(R2)",
      "section_number": "7.2.1",
      "section_title": "The IB should include a summary of the relevant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic, and clinical information available that is relevant to the stage of clinical development of the investigational product.",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8dc41e744652",
    "chunk_index": 2,
    "text": "7.4 Minimum Information Should Be Included\nThe IB should contain the minimum amount of information required for the particular stage of drug development.",
    "char_count": 153,
    "word_count": 23,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "7",
      "title": "Investigator's Brochure",
      "version": "E6(R2)",
      "section_number": "7.4",
      "section_title": "Minimum Information Should Be Included",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_515f9f4bda70",
    "chunk_index": 0,
    "text": "8.1 Introduction\nEssential Documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements.",
    "char_count": 361,
    "word_count": 52,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "8",
      "title": "Essential Documents for the Conduct of a Clinical Trial",
      "version": "E6(R2)",
      "section_number": "8.1",
      "section_title": "Introduction",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_82158da8a51d",
    "chunk_index": 1,
    "text": "8.2 Before the Clinical Phase of the Trial Commences\nDuring this planning stage the following documents should be generated and should be on file before the trial formally starts:",
    "char_count": 179,
    "word_count": 29,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "8",
      "title": "Essential Documents for the Conduct of a Clinical Trial",
      "version": "E6(R2)",
      "section_number": "8.2",
      "section_title": "Before the Clinical Phase of the Trial Commences",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0ad281a9b122",
    "chunk_index": 2,
    "text": "8.4 After Completion or Termination of the Trial\nAfter completion or termination of the trial, all of the documents identified in sections 8.2 and 8.3 should be in the file together with the following:",
    "char_count": 201,
    "word_count": 34,
    "metadata": {
      "source": "ich_gcp",
      "source_name": "ICH-GCP E6(R2) Guidelines",
      "document_type": "regulatory_guideline",
      "section_id": "8",
      "title": "Essential Documents for the Conduct of a Clinical Trial",
      "version": "E6(R2)",
      "section_number": "8.4",
      "section_title": "After Completion or Termination of the Trial",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_fa08f1c1dc02",
    "chunk_index": 0,
    "text": "DATA QUALITY INDEX (DQI) OVERVIEW\n\nThe Data Quality Index (DQI) is a composite score measuring overall data quality for clinical trial subjects. It ranges from 0-100, with higher scores indicating better data quality.",
    "char_count": 217,
    "word_count": 33,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DATA QUALITY INDEX (DQI) OVERVIEW",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_129221141f57",
    "chunk_index": 0,
    "text": "1. Safety Score (25%): Measures SAE reconciliation and safety data completeness\n - SAE-DM discrepancies between data management and safety teams\n - SAE-Safety pending items requiring physician review\n - Critical for patient safety and regulatory compliance\n\n2. Query Score (20%): Measures query management efficiency\n - Open queries requiring resolution\n - Query aging (older queries penalized more heavily)\n - Query types: DM queries, clinical queries, medical queries, site queries",
    "char_count": 483,
    "word_count": 67,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DQI COMPONENTS AND WEIGHTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_af894c4b9cdb",
    "chunk_index": 1,
    "text": "3. Completeness Score (15%): Measures data collection completeness\n - Missing visits that should have been completed\n - Missing CRF pages within visits\n - Days outstanding for missing data\n\n4. Coding Score (12%): Measures medical/drug coding status\n - MedDRA coding for adverse events and medical history\n - WHODrug coding for concomitant medications\n - Uncoded terms block database lock",
    "char_count": 387,
    "word_count": 57,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DQI COMPONENTS AND WEIGHTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a873bab6daa8",
    "chunk_index": 2,
    "text": "5. Lab Score (10%): Measures laboratory data quality\n - Missing lab values\n - Out-of-range values requiring confirmation\n - Lab name/range issues\n\n6. SDV Score (8%): Measures source data verification progress\n - CRFs requiring SDV that have been verified\n - SDV completion rate per subject\n\n7. Signature Score (5%): Measures electronic signature compliance\n - CRFs requiring signatures that are signed\n - Overdue signatures (within 45 days, beyond 90 days)\n - Broken signatures requiring re-signing",
    "char_count": 498,
    "word_count": 73,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DQI COMPONENTS AND WEIGHTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_5502ad418165",
    "chunk_index": 4,
    "text": "DQI MULTIPLIERS\n\n- Age Multiplier: Issues older than 30 days receive 1.6x penalty\n- Criticality Multiplier: Safety issues receive 1.5x penalty\n- Trend Multiplier: Worsening trends receive 1.25x penalty",
    "char_count": 201,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DQI MULTIPLIERS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_c86bfec14a8b",
    "chunk_index": 5,
    "text": "DQI BANDS\n\n- Pristine (95-100): Exceptional quality, ready for lock\n- Excellent (85-95): Minor issues only\n- Good (75-85): Some attention needed\n- Fair (65-75): Significant issues present\n- Poor (50-65): Major intervention required\n- Critical (25-50): Immediate action needed\n- Emergency (<25): Trial integrity at risk",
    "char_count": 318,
    "word_count": 47,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "DQI BANDS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_8feeae696f71",
    "chunk_index": 6,
    "text": "BEST PRACTICES\n\n1. Monitor DQI weekly at minimum\n2. Focus on high-weight components first (Safety, Query)\n3. Address aging issues before they accumulate penalties\n4. Use cascade analysis to find root causes\n5. Track trends to predict future issues",
    "char_count": 247,
    "word_count": 39,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-001",
      "category": "data_quality",
      "title": "Data Quality Index (DQI) Management",
      "keywords": [
        "DQI",
        "data quality",
        "score",
        "metrics",
        "components",
        "weights"
      ],
      "related_sections": [
        "DQ-002",
        "DQ-003",
        "CL-001"
      ],
      "section_title": "BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_047170d7977e",
    "chunk_index": 0,
    "text": "QUERY MANAGEMENT IN CLINICAL TRIALS\n\nQueries are formal requests for clarification or correction of clinical trial data. Effective query management is critical for data quality and timely database lock.",
    "char_count": 202,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "QUERY MANAGEMENT IN CLINICAL TRIALS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_b434fb5ea927",
    "chunk_index": 1,
    "text": "QUERY TYPES\n\n1. DM Queries: Generated by data management for data discrepancies\n2. Clinical Queries: Medical/clinical questions about subject data\n3. Medical Queries: Require medical monitor review\n4. Site Queries: Administrative or procedural questions\n5. Coding Queries: Questions about adverse event or medication coding\n6. Safety Queries: Related to safety reporting discrepancies",
    "char_count": 384,
    "word_count": 52,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "QUERY TYPES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_2dd5b1b86498",
    "chunk_index": 2,
    "text": "QUERY LIFECYCLE\n\n1. Generation: Query created (auto or manual)\n2. Open: Query sent to site for response\n3. Answered: Site provides response\n4. Closed: Response accepted, query resolved\n5. Re-opened: Response insufficient, additional clarification needed",
    "char_count": 253,
    "word_count": 35,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "QUERY LIFECYCLE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ef0af11f38cc",
    "chunk_index": 3,
    "text": "QUERY AGING CATEGORIES\n\n- Fresh (0-7 days): Normal processing time\n- Aging (8-14 days): Requires attention\n- Overdue (15-30 days): Escalation needed\n- Critical (>30 days): Immediate intervention required",
    "char_count": 203,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "QUERY AGING CATEGORIES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_83240f063106",
    "chunk_index": 4,
    "text": "QUERY RESOLUTION STRATEGIES\n\n1. Batch Processing: Group similar queries for efficient resolution\n2. Priority Triage: Address safety and critical queries first\n3. Root Cause Analysis: Identify patterns to prevent future queries\n4. Site Training: Reduce query volume through education\n5. Template Responses: Standardize common query responses",
    "char_count": 340,
    "word_count": 46,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "QUERY RESOLUTION STRATEGIES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a31210db5478",
    "chunk_index": 5,
    "text": "ESCALATION PROCEDURES\n\n- Day 7: First reminder to site\n- Day 14: CRA follow-up\n- Day 21: Site management notification\n- Day 30: Study lead escalation\n- Day 45+: Sponsor notification",
    "char_count": 181,
    "word_count": 31,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "ESCALATION PROCEDURES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_98bae335d933",
    "chunk_index": 6,
    "text": "BEST PRACTICES\n\n1. Respond to queries within 5 business days\n2. Provide complete answers to avoid re-opening\n3. Include source documentation when available\n4. Address root cause, not just symptoms\n5. Use cascade analysis to prioritize",
    "char_count": 234,
    "word_count": 36,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-002",
      "category": "data_quality",
      "title": "Query Management Best Practices",
      "keywords": [
        "query",
        "queries",
        "resolution",
        "aging",
        "escalation",
        "data clarification"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "SI-001"
      ],
      "section_title": "BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_3e33c70e282f",
    "chunk_index": 0,
    "text": "SDV REQUIREMENTS\n\n1. 100% SDV: All data points verified against source\n2. Risk-Based SDV: Targeted verification based on risk assessment\n3. Reduced SDV: Verification of critical data points only",
    "char_count": 194,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-003",
      "category": "data_quality",
      "title": "Source Data Verification (SDV) Procedures",
      "keywords": [
        "SDV",
        "source data verification",
        "monitoring",
        "CRA",
        "source documents"
      ],
      "related_sections": [
        "DQ-001",
        "MO-001",
        "SI-002"
      ],
      "section_title": "SDV REQUIREMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_46e0d22d0fb0",
    "chunk_index": 1,
    "text": "SDV-REQUIRED DATA TYPICALLY INCLUDES\n\n- Informed consent date and signature\n- Eligibility criteria\n- Primary endpoint data\n- Serious adverse events\n- Protocol deviations\n- Study drug administration\n- Key safety assessments",
    "char_count": 222,
    "word_count": 32,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-003",
      "category": "data_quality",
      "title": "Source Data Verification (SDV) Procedures",
      "keywords": [
        "SDV",
        "source data verification",
        "monitoring",
        "CRA",
        "source documents"
      ],
      "related_sections": [
        "DQ-001",
        "MO-001",
        "SI-002"
      ],
      "section_title": "SDV-REQUIRED DATA TYPICALLY INCLUDES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_e461de7cc1c3",
    "chunk_index": 2,
    "text": "SDV PROCESS\n\n1. CRA accesses source documents at site\n2. Compares each data point to CRF entry\n3. Documents any discrepancies found\n4. Generates queries for corrections\n5. Records SDV completion in monitoring report",
    "char_count": 215,
    "word_count": 34,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-003",
      "category": "data_quality",
      "title": "Source Data Verification (SDV) Procedures",
      "keywords": [
        "SDV",
        "source data verification",
        "monitoring",
        "CRA",
        "source documents"
      ],
      "related_sections": [
        "DQ-001",
        "MO-001",
        "SI-002"
      ],
      "section_title": "SDV PROCESS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_35390fb6fd4b",
    "chunk_index": 3,
    "text": "SDV BEST PRACTICES\n\n1. Complete SDV during each monitoring visit\n2. Prioritize safety and efficacy data\n3. Document all findings thoroughly\n4. Follow up on outstanding issues\n5. Update monitoring reports promptly",
    "char_count": 212,
    "word_count": 32,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DQ-003",
      "category": "data_quality",
      "title": "Source Data Verification (SDV) Procedures",
      "keywords": [
        "SDV",
        "source data verification",
        "monitoring",
        "CRA",
        "source documents"
      ],
      "related_sections": [
        "DQ-001",
        "MO-001",
        "SI-002"
      ],
      "section_title": "SDV BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_da43d1480abb",
    "chunk_index": 0,
    "text": "Clean Patient status indicates a subject's data is ready for database lock. TRIALPULSE uses a two-tier system.\n\nTIER 1: CLINICAL CLEAN (Hard Blocks)\nThese criteria MUST be met for clinical data integrity:\n\n1. No Missing Visits (visit_missing_visit_count = 0)\n - All protocol-required visits completed\n - Visit data entered in EDC\n\n2. No Missing Pages (pages_missing_page_count = 0)\n - All required CRF pages completed\n - No blank or partially completed forms",
    "char_count": 458,
    "word_count": 70,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "TWO-TIER CLEAN PATIENT DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a0fe13437f07",
    "chunk_index": 1,
    "text": "3. No Open Queries (total_open_queries = 0)\n - All queries resolved and closed\n - No pending clarifications\n\n4. SDV Complete (crfs_source_data_verified = crfs_requiring_sdv)\n - All required SDV performed\n - 100% verification rate\n\n5. Signatures Complete (crfs_signed >= crfs_requiring_signature)\n - All required signatures obtained\n - No pending PI signatures\n\n6. MedDRA Coding Complete (meddra_coded_terms = meddra_total_terms)\n - All adverse events coded\n - No pending medical coding",
    "char_count": 485,
    "word_count": 65,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "TWO-TIER CLEAN PATIENT DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ad057b170623",
    "chunk_index": 2,
    "text": "7. WHODrug Coding Complete (whodrug_coded_terms = whodrug_total_terms)\n - All medications coded\n - No pending drug coding\n\nTIER 2: OPERATIONAL CLEAN (Soft Blocks)\nAdditional criteria for operational readiness:\n\n1. No Lab Issues (lab_issue_count = 0)\n - No missing lab values\n - No unconfirmed out-of-range values\n\n2. No SAE-DM Pending (sae_dm_pending = 0)\n - All SAE data reconciled\n - DM and Safety aligned",
    "char_count": 407,
    "word_count": 61,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "TWO-TIER CLEAN PATIENT DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_e55f8864454f",
    "chunk_index": 3,
    "text": "2. No SAE-DM Pending (sae_dm_pending = 0)\n - All SAE data reconciled\n - DM and Safety aligned\n\n3. No SAE-Safety Pending (sae_safety_pending = 0)\n - All safety reviews complete\n - No pending physician review\n\n4. No EDRR Issues (edrr_issue_count = 0)\n - External data reconciled\n - No third-party discrepancies\n\n5. No Overdue Signatures (crfs_overdue_for_signs = 0)\n - No aging signature issues\n - All signatures current",
    "char_count": 418,
    "word_count": 65,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "TWO-TIER CLEAN PATIENT DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_d11a2ac01d99",
    "chunk_index": 4,
    "text": "6. No Broken Signatures (broken_signatures = 0)\n - No invalidated signatures\n - All e-signatures valid\n\n7. No Inactivated Forms (inactivated_total = 0)\n - No deactivated pages requiring review\n - All form status resolved",
    "char_count": 220,
    "word_count": 33,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "TWO-TIER CLEAN PATIENT DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ba385af85fdb",
    "chunk_index": 5,
    "text": "EFFORT ESTIMATION\n\nEach blocking criterion has estimated resolution time:\n- Missing Visit: 2 hours (site)\n- Missing Page: 1.5 hours (site)\n- Open Query: 0.5 hours (site/DM)\n- SDV: 0.25 hours per CRF (CRA)\n- Signature: 0.1 hours per form (site)\n- Coding: 0.15 hours per term (coder)",
    "char_count": 281,
    "word_count": 48,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-001",
      "category": "clean_patient",
      "title": "Two-Tier Clean Patient Definition",
      "keywords": [
        "clean patient",
        "tier 1",
        "tier 2",
        "hard blocks",
        "soft blocks",
        "database lock"
      ],
      "related_sections": [
        "DQ-001",
        "CL-002",
        "DB-001"
      ],
      "section_title": "EFFORT ESTIMATION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_309ac1e31bfe",
    "chunk_index": 0,
    "text": "This guide provides resolution strategies for each blocking criterion.\n\n1. MISSING VISITS\nRoot Causes:\n- Subject missed scheduled visit\n- Visit not entered in EDC\n- Visit scheduled but not completed\n\nResolution Steps:\na. Check if visit was completed but not entered\nb. Verify if visit was rescheduled\nc. If visit missed, document reason\nd. If visit cannot be recovered, document as protocol deviation\ne. Update visit status in EDC\n\nResponsible: Site Coordinator, CRA",
    "char_count": 466,
    "word_count": 74,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-002",
      "category": "clean_patient",
      "title": "Blocking Reason Resolution Guide",
      "keywords": [
        "blocking reason",
        "resolution",
        "missing visits",
        "queries",
        "SDV",
        "signatures",
        "coding"
      ],
      "related_sections": [
        "CL-001",
        "DQ-002",
        "DQ-003"
      ],
      "section_title": "BLOCKING REASON RESOLUTION GUIDE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_5d41a056131a",
    "chunk_index": 1,
    "text": "Responsible: Site Coordinator, CRA\n\n2. MISSING PAGES\nRoot Causes:\n- Form not completed during visit\n- Data entry incomplete\n- Form inadvertently skipped\n\nResolution Steps:\na. Review source documents for data\nb. Complete missing CRF pages\nc. If data unavailable, query site\nd. Document reason for missing data\ne. Obtain required signatures\n\nResponsible: Site Coordinator, Data Manager\n\n3. OPEN QUERIES\nRoot Causes:\n- Data discrepancy identified\n- Clarification needed\n- Incomplete data entry",
    "char_count": 490,
    "word_count": 73,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-002",
      "category": "clean_patient",
      "title": "Blocking Reason Resolution Guide",
      "keywords": [
        "blocking reason",
        "resolution",
        "missing visits",
        "queries",
        "SDV",
        "signatures",
        "coding"
      ],
      "related_sections": [
        "CL-001",
        "DQ-002",
        "DQ-003"
      ],
      "section_title": "BLOCKING REASON RESOLUTION GUIDE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_6fdafa345f0c",
    "chunk_index": 2,
    "text": "Resolution Steps:\na. Review query details\nb. Check source documents\nc. Provide complete response\nd. Make CRF corrections if needed\ne. Verify query closure\n\nResponsible: Site (response), Data Manager (review)\n\n4. SDV INCOMPLETE\nRoot Causes:\n- Monitoring visit not scheduled\n- Source documents not available\n- CRA access issues\n\nResolution Steps:\na. Schedule monitoring visit\nb. Prepare source documents\nc. Complete SDV during visit\nd. Document in monitoring report\ne. Close any discrepancies found",
    "char_count": 496,
    "word_count": 74,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-002",
      "category": "clean_patient",
      "title": "Blocking Reason Resolution Guide",
      "keywords": [
        "blocking reason",
        "resolution",
        "missing visits",
        "queries",
        "SDV",
        "signatures",
        "coding"
      ],
      "related_sections": [
        "CL-001",
        "DQ-002",
        "DQ-003"
      ],
      "section_title": "BLOCKING REASON RESOLUTION GUIDE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_034e159fa4f4",
    "chunk_index": 3,
    "text": "Responsible: CRA, Site Coordinator\n\n5. SIGNATURES PENDING\nRoot Causes:\n- PI/Sub-I not available\n- Signature workflow not initiated\n- Technical issues with e-signature\n\nResolution Steps:\na. Notify PI of pending signatures\nb. Schedule signature session\nc. Complete batch signatures\nd. Verify signature completion\ne. Re-sign any broken signatures\n\nResponsible: Site (PI/Sub-I)\n\n6. CODING INCOMPLETE\nRoot Causes:\n- New terms requiring coding\n- Ambiguous verbatim terms\n- Coding backlog",
    "char_count": 481,
    "word_count": 68,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-002",
      "category": "clean_patient",
      "title": "Blocking Reason Resolution Guide",
      "keywords": [
        "blocking reason",
        "resolution",
        "missing visits",
        "queries",
        "SDV",
        "signatures",
        "coding"
      ],
      "related_sections": [
        "CL-001",
        "DQ-002",
        "DQ-003"
      ],
      "section_title": "BLOCKING REASON RESOLUTION GUIDE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_39623d6a0398",
    "chunk_index": 4,
    "text": "Resolution Steps:\na. Review uncoded terms\nb. Apply standard coding\nc. Escalate ambiguous terms\nd. Request site clarification if needed\ne. Document coding decisions\n\nResponsible: Medical Coder\n\n7. SAE RECONCILIATION\nRoot Causes:\n- Data entry timing differences\n- Missing SAE forms\n- Discrepant information\n\nResolution Steps:\na. Compare DM and Safety records\nb. Identify discrepancies\nc. Request missing forms\nd. Reconcile conflicting data\ne. Confirm alignment\n\nResponsible: Safety Data Manager",
    "char_count": 492,
    "word_count": 70,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CL-002",
      "category": "clean_patient",
      "title": "Blocking Reason Resolution Guide",
      "keywords": [
        "blocking reason",
        "resolution",
        "missing visits",
        "queries",
        "SDV",
        "signatures",
        "coding"
      ],
      "related_sections": [
        "CL-001",
        "DQ-002",
        "DQ-003"
      ],
      "section_title": "BLOCKING REASON RESOLUTION GUIDE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_fd48deafc4eb",
    "chunk_index": 0,
    "text": "DATABASE LOCK READINESS ASSESSMENT\n\nDatabase lock is the point at which clinical trial data is frozen for statistical analysis. Proper preparation is critical for data integrity and regulatory compliance.",
    "char_count": 204,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DATABASE LOCK READINESS ASSESSMENT",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ed91094d4a5b",
    "chunk_index": 1,
    "text": "DB LOCK ELIGIBILITY\n\nSubjects eligible for DB Lock assessment:\n- Completed: Finished all protocol visits\n- Discontinued: Early termination with data complete\n- Ongoing: May be locked if all available data clean\n\nSubjects NOT eligible:\n- Screen Failures: Excluded from efficacy analysis\n- Screening: Still in screening process\n- Unknown Status: Status needs clarification",
    "char_count": 370,
    "word_count": 54,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DB LOCK ELIGIBILITY",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_dba001b36a7d",
    "chunk_index": 2,
    "text": "DB LOCK READINESS TIERS\n\nTIER 1: FULLY READY\n- All Tier 1 Clean criteria met\n- All Tier 2 Clean criteria met\n- No pending issues of any kind\n- Can be locked immediately\n\nTIER 2: PENDING\n- Tier 1 Clean (hard blocks resolved)\n- Some Tier 2 issues remain\n- Can be frozen pending final cleanup\n- 1-7 days to full readiness\n\nTIER 3: BLOCKED\n- One or more hard blocks present\n- Cannot proceed to lock\n- Requires active intervention\n- Timeline depends on issue severity",
    "char_count": 462,
    "word_count": 88,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DB LOCK READINESS TIERS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_c3290e4c30a2",
    "chunk_index": 3,
    "text": "DB LOCK PROCESS\n\n1. Pre-Lock Activities:\n   - Complete all data entry\n   - Resolve all queries\n   - Complete SDV and signatures\n   - Reconcile external data\n   - Freeze subject data\n\n2. Data Review:\n   - Medical review of key data\n   - Safety review complete\n   - Protocol deviation review\n   - Eligibility confirmation\n\n3. Lock Execution:\n   - Lock subjects in batches\n   - Document lock status\n   - Archive essential documents\n   - Notify stakeholders\n\n4. Post-Lock Activities:\n   - Statistical analysis\n   - Data export\n   - Archive procedures\n   - Unlock procedures (if needed)",
    "char_count": 581,
    "word_count": 84,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DB LOCK PROCESS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_fecb6959bc52",
    "chunk_index": 4,
    "text": "DB LOCK METRICS\n\n- % Ready: Subjects meeting all criteria\n- Days to Ready: Average time to resolve issues\n- Blocking Reasons: Distribution of issues\n- Trend: Improvement over time",
    "char_count": 179,
    "word_count": 30,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DB LOCK METRICS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ec43bf0e36f3",
    "chunk_index": 5,
    "text": "CRITICAL PATH TO LOCK\n\nUse cascade analysis to identify:\n1. Issues blocking most subjects\n2. Dependencies between issues\n3. Optimal resolution sequence\n4. Resource requirements",
    "char_count": 176,
    "word_count": 25,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "CRITICAL PATH TO LOCK",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_78186f1e354c",
    "chunk_index": 6,
    "text": "DB LOCK TIMELINE\n\n- 4 weeks before: 80% Tier 2 clean target\n- 2 weeks before: 95% Tier 1 clean target\n- 1 week before: All subjects frozen\n- Lock day: Final lock execution",
    "char_count": 171,
    "word_count": 34,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-001",
      "category": "database_lock",
      "title": "Database Lock Readiness Assessment",
      "keywords": [
        "database lock",
        "DB lock",
        "readiness",
        "freeze",
        "data integrity"
      ],
      "related_sections": [
        "CL-001",
        "CL-002",
        "DB-002"
      ],
      "section_title": "DB LOCK TIMELINE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_abdf43bea287",
    "chunk_index": 0,
    "text": "Database Lock Checklist\n\nDATABASE LOCK CHECKLIST\n\nPre-Lock Verification Checklist:\n\nDATA ENTRY COMPLETE:\n All CRF pages entered\n All visits completed or documented\n All protocol deviations recorded\n All AEs/SAEs entered and coded\n All concomitant medications entered\n\nQUERIES RESOLVED:\n All queries closed\n No pending query responses\n Query resolution documented\n Final query review complete",
    "char_count": 400,
    "word_count": 59,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-002",
      "category": "database_lock",
      "title": "Database Lock Checklist",
      "keywords": [
        "checklist",
        "database lock",
        "verification",
        "approval",
        "pre-lock"
      ],
      "related_sections": [
        "DB-001",
        "CL-001",
        "SA-001"
      ]
    }
  },
  {
    "chunk_id": "chunk_aa11f07bc95d",
    "chunk_index": 1,
    "text": "SDV COMPLETE:\n 100% SDV for required fields\n SDV documented in monitoring reports\n All discrepancies resolved\n Final monitoring visit complete\n\nSIGNATURES OBTAINED:\n All PI signatures complete\n All required e-signatures valid\n No broken signatures\n Signature log current\n\nCODING COMPLETE:\n All AEs coded (MedDRA)\n All medications coded (WHODrug)\n Coding review complete\n Coding dictionaries locked",
    "char_count": 409,
    "word_count": 63,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-002",
      "category": "database_lock",
      "title": "Database Lock Checklist",
      "keywords": [
        "checklist",
        "database lock",
        "verification",
        "approval",
        "pre-lock"
      ],
      "related_sections": [
        "DB-001",
        "CL-001",
        "SA-001"
      ]
    }
  },
  {
    "chunk_id": "chunk_86fc33b8c620",
    "chunk_index": 2,
    "text": "SAFETY DATA:\n SAE reconciliation complete\n DM-Safety alignment verified\n All safety reviews finalized\n Safety database locked\n\nEXTERNAL DATA:\n Lab data reconciled\n ECG data reconciled\n Central imaging reviewed\n EDRR issues resolved\n\nREGULATORY:\n Protocol deviations assessed\n Eligibility confirmed\n Essential documents complete\n Audit trail verified\n\nSYSTEM CHECKS:\n Edit checks passed\n Validation rules satisfied\n Data export tested\n Archive procedures ready",
    "char_count": 475,
    "word_count": 71,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-002",
      "category": "database_lock",
      "title": "Database Lock Checklist",
      "keywords": [
        "checklist",
        "database lock",
        "verification",
        "approval",
        "pre-lock"
      ],
      "related_sections": [
        "DB-001",
        "CL-001",
        "SA-001"
      ]
    }
  },
  {
    "chunk_id": "chunk_afdcf380a25d",
    "chunk_index": 3,
    "text": "APPROVALS:\n Data management approval\n Medical monitor approval\n Study lead approval\n Sponsor approval\n\nPOST-LOCK PROCEDURES:\n Unblinding plan ready\n Analysis datasets defined\n Statistical analysis plan final\n Archive procedures documented",
    "char_count": 246,
    "word_count": 35,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "DB-002",
      "category": "database_lock",
      "title": "Database Lock Checklist",
      "keywords": [
        "checklist",
        "database lock",
        "verification",
        "approval",
        "pre-lock"
      ],
      "related_sections": [
        "DB-001",
        "CL-001",
        "SA-001"
      ]
    }
  },
  {
    "chunk_id": "chunk_af71cc1f4f3c",
    "chunk_index": 0,
    "text": "SERIOUS ADVERSE EVENT (SAE) REPORTING AND RECONCILIATION\n\nSAE DEFINITION (ICH E2A):\nA Serious Adverse Event is any untoward medical occurrence that:\n- Results in death\n- Is life-threatening\n- Requires inpatient hospitalization or prolongation of existing hospitalization\n- Results in persistent or significant disability/incapacity\n- Is a congenital anomaly/birth defect\n- Is an important medical event",
    "char_count": 402,
    "word_count": 56,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SERIOUS ADVERSE EVENT (SAE) REPORTING AND RECONCILIATION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_7d8624089f2e",
    "chunk_index": 1,
    "text": "SAE REPORTING TIMELINE\n\n- Fatal/Life-threatening: Within 24 hours of awareness\n- Other SAEs: Within 24-72 hours per protocol\n- Follow-up reports: Within 24 hours of new information",
    "char_count": 180,
    "word_count": 27,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SAE REPORTING TIMELINE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_efd36d069bb8",
    "chunk_index": 2,
    "text": "SAE REPORTING WORKFLOW\n\n1. Site identifies SAE\n2. Complete initial SAE form\n3. Submit to sponsor/safety team\n4. Enter in EDC (Data Management)\n5. Safety team reviews\n6. Regulatory reporting if required\n7. Follow-up until resolution",
    "char_count": 231,
    "word_count": 36,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SAE REPORTING WORKFLOW",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a06a3a842b28",
    "chunk_index": 3,
    "text": "SAE RECONCILIATION\n\nPurpose: Ensure alignment between:\n- Data Management (EDC entries)\n- Safety Database (safety system entries)\n- Regulatory submissions\n\nReconciliation Process:\n1. Compare SAE listings from both systems\n2. Identify discrepancies:\n   - Missing SAEs (in one system only)\n   - Date discrepancies\n   - Outcome discrepancies\n   - Causality discrepancies\n3. Investigate root cause\n4. Correct errors in appropriate system\n5. Document reconciliation\n6. Confirm alignment",
    "char_count": 480,
    "word_count": 64,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SAE RECONCILIATION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_0a5405a089ef",
    "chunk_index": 4,
    "text": "SAE METRICS\n\n- SAE-DM pending: SAEs awaiting DM completion\n- SAE-Safety pending: SAEs awaiting safety review\n- Reconciliation rate: % aligned between systems\n- Reporting compliance: % within timeline",
    "char_count": 199,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SAE METRICS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_d900c2e9ef4a",
    "chunk_index": 5,
    "text": "SAE DOCUMENTATION REQUIREMENTS\n\n- Event description\n- Onset and resolution dates\n- Severity and seriousness criteria\n- Relationship to study drug\n- Action taken with study drug\n- Outcome\n- Reporter information",
    "char_count": 209,
    "word_count": 32,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-001",
      "category": "safety",
      "title": "SAE Reporting and Reconciliation",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "reconciliation",
        "pharmacovigilance"
      ],
      "related_sections": [
        "SA-002",
        "DQ-001",
        "CL-001"
      ],
      "section_title": "SAE DOCUMENTATION REQUIREMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_b8837306677a",
    "chunk_index": 0,
    "text": "SIGNAL SOURCES\n\n1. Individual case reports (SAEs/AEs)\n2. Aggregate safety data analysis\n3. Literature reports\n4. Regulatory authority notifications\n5. Post-marketing reports",
    "char_count": 173,
    "word_count": 22,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-002",
      "category": "safety",
      "title": "Safety Signal Detection",
      "keywords": [
        "safety signal",
        "detection",
        "pharmacovigilance",
        "adverse events",
        "patterns"
      ],
      "related_sections": [
        "SA-001",
        "AN-001",
        "PA-001"
      ],
      "section_title": "SIGNAL SOURCES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_7bf87c49f6f5",
    "chunk_index": 1,
    "text": "SIGNAL DETECTION METHODS\n\nQuantitative Methods:\n- Proportional Reporting Ratio (PRR)\n- Reporting Odds Ratio (ROR)\n- Bayesian methods (BCPNN, MGPS)\n- Time-to-onset analysis\n\nQualitative Methods:\n- Clinical review of individual cases\n- Pattern recognition\n- Expert assessment\n- Literature review",
    "char_count": 293,
    "word_count": 40,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-002",
      "category": "safety",
      "title": "Safety Signal Detection",
      "keywords": [
        "safety signal",
        "detection",
        "pharmacovigilance",
        "adverse events",
        "patterns"
      ],
      "related_sections": [
        "SA-001",
        "AN-001",
        "PA-001"
      ],
      "section_title": "SIGNAL DETECTION METHODS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ecacebd49521",
    "chunk_index": 2,
    "text": "SIGNAL CRITERIA\n\nStatistical threshold: Typically >2 above baseline\nConsiderations:\n- Number of cases\n- Biological plausibility\n- Temporal relationship\n- Dose-response relationship\n- Consistency across studies",
    "char_count": 210,
    "word_count": 26,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-002",
      "category": "safety",
      "title": "Safety Signal Detection",
      "keywords": [
        "safety signal",
        "detection",
        "pharmacovigilance",
        "adverse events",
        "patterns"
      ],
      "related_sections": [
        "SA-001",
        "AN-001",
        "PA-001"
      ],
      "section_title": "SIGNAL CRITERIA",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ef0b02efd418",
    "chunk_index": 3,
    "text": "SIGNAL RESPONSE\n\n1. Detection: Identify potential signal\n2. Validation: Confirm signal is real\n3. Analysis: Characterize signal\n4. Assessment: Evaluate clinical significance\n5. Action: Determine response\n6. Communication: Notify stakeholders\n7. Monitoring: Continue surveillance",
    "char_count": 278,
    "word_count": 34,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-002",
      "category": "safety",
      "title": "Safety Signal Detection",
      "keywords": [
        "safety signal",
        "detection",
        "pharmacovigilance",
        "adverse events",
        "patterns"
      ],
      "related_sections": [
        "SA-001",
        "AN-001",
        "PA-001"
      ],
      "section_title": "SIGNAL RESPONSE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_2c59d288ca18",
    "chunk_index": 4,
    "text": "TRIALPULSE PATTERN DETECTION\n\nThe system monitors for:\n- Cluster patterns (same AE at multiple sites)\n- Temporal patterns (AE onset timing)\n- Demographic patterns (specific populations)\n- Geographic patterns (regional differences)\n\nAlert triggers when:\n- AE rate > 2 above baseline\n- Cluster of similar AEs detected\n- Unexpected AE pattern identified",
    "char_count": 351,
    "word_count": 52,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SA-002",
      "category": "safety",
      "title": "Safety Signal Detection",
      "keywords": [
        "safety signal",
        "detection",
        "pharmacovigilance",
        "adverse events",
        "patterns"
      ],
      "related_sections": [
        "SA-001",
        "AN-001",
        "PA-001"
      ],
      "section_title": "TRIALPULSE PATTERN DETECTION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_330e36163763",
    "chunk_index": 0,
    "text": "RISK-BASED MONITORING (RBM) APPROACH\n\nRBM DEFINITION\n\nRisk-Based Monitoring is an adaptive approach that directs monitoring activities based on risk assessment, focusing resources on critical data and processes.\n\nICH E6(R2) REQUIREMENTS:\n- Quality management approach\n- Risk-proportionate monitoring\n- Centralized monitoring as primary method\n- On-site monitoring as supplement",
    "char_count": 377,
    "word_count": 48,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-001",
      "category": "monitoring",
      "title": "Risk-Based Monitoring Approach",
      "keywords": [
        "monitoring",
        "risk-based",
        "RBM",
        "KRI",
        "centralized monitoring",
        "on-site"
      ],
      "related_sections": [
        "MO-002",
        "DQ-003",
        "SI-001"
      ],
      "section_title": "RISK-BASED MONITORING (RBM) APPROACH\n\nRBM DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a16c713f64a4",
    "chunk_index": 1,
    "text": "RISK ASSESSMENT COMPONENTS\n\n1. Risk Identification:\n- Subject safety risks\n- Data integrity risks\n- Protocol compliance risks\n- Operational risks\n\n2. Risk Evaluation:\n- Likelihood of occurrence\n- Impact if occurs\n- Detectability\n- Risk priority number (RPN)\n\n3. Risk Control:\n- Prevention measures\n- Detection measures\n- Mitigation actions",
    "char_count": 339,
    "word_count": 51,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-001",
      "category": "monitoring",
      "title": "Risk-Based Monitoring Approach",
      "keywords": [
        "monitoring",
        "risk-based",
        "RBM",
        "KRI",
        "centralized monitoring",
        "on-site"
      ],
      "related_sections": [
        "MO-002",
        "DQ-003",
        "SI-001"
      ],
      "section_title": "RISK ASSESSMENT COMPONENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_12a265c3309e",
    "chunk_index": 2,
    "text": "MONITORING MODALITIES\n\nCentralized Monitoring:\n- Remote data review\n- Statistical analyses\n- Key Risk Indicators (KRIs)\n- Cross-site comparisons\n- Trend analysis\n\nOn-Site Monitoring:\n- SDV of critical data\n- Source document review\n- Site staff interviews\n- Facility inspection\n- Protocol compliance verification\n\nKEY RISK INDICATORS (KRIs):\n- Enrollment rate\n- Screen failure rate\n- Protocol deviation rate\n- Query rate\n- SAE rate\n- Data entry timeliness\n- Missing data rate",
    "char_count": 474,
    "word_count": 73,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-001",
      "category": "monitoring",
      "title": "Risk-Based Monitoring Approach",
      "keywords": [
        "monitoring",
        "risk-based",
        "RBM",
        "KRI",
        "centralized monitoring",
        "on-site"
      ],
      "related_sections": [
        "MO-002",
        "DQ-003",
        "SI-001"
      ],
      "section_title": "MONITORING MODALITIES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_364257cdce28",
    "chunk_index": 3,
    "text": "MONITORING PLAN ELEMENTS\n\n1. Risk assessment summary\n2. Monitoring strategy (central vs. on-site)\n3. Visit frequency and triggers\n4. SDV strategy\n5. Essential data verification\n6. Escalation procedures\n7. Documentation requirements",
    "char_count": 231,
    "word_count": 31,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-001",
      "category": "monitoring",
      "title": "Risk-Based Monitoring Approach",
      "keywords": [
        "monitoring",
        "risk-based",
        "RBM",
        "KRI",
        "centralized monitoring",
        "on-site"
      ],
      "related_sections": [
        "MO-002",
        "DQ-003",
        "SI-001"
      ],
      "section_title": "MONITORING PLAN ELEMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_811f70b38703",
    "chunk_index": 0,
    "text": "1. ADMINISTRATIVE INFORMATION:\n- Visit date and type\n- Site identification\n- Monitor name and signature\n- Persons met\n- Previous visit date\n\n2. SUBJECT STATUS:\n- Enrolled subjects\n- Screen failures\n- Discontinuations\n- Completed subjects\n- Active subjects\n\n3. INFORMED CONSENT REVIEW:\n- Consents reviewed\n- Issues identified\n- Re-consent requirements\n\n4. SOURCE DATA VERIFICATION:\n- Subjects reviewed\n- Data points verified\n- Discrepancies found\n- Corrections made",
    "char_count": 464,
    "word_count": 70,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-002",
      "category": "monitoring",
      "title": "Monitoring Visit Report Requirements",
      "keywords": [
        "monitoring report",
        "visit report",
        "documentation",
        "CRA",
        "findings"
      ],
      "related_sections": [
        "MO-001",
        "ES-001",
        "DQ-003"
      ],
      "section_title": "REPORT SECTIONS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_746b6f755d12",
    "chunk_index": 1,
    "text": "5. INVESTIGATIONAL PRODUCT:\n- Accountability review\n- Storage conditions\n- Expiry dates\n- Dispensing records\n\n6. ESSENTIAL DOCUMENTS:\n- Documents reviewed\n- Updates needed\n- Filing compliance\n\n7. PROTOCOL DEVIATIONS:\n- New deviations identified\n- Previous deviations status\n- Corrective actions\n\n8. SAFETY REVIEW:\n- SAE review\n- AE documentation\n- Reporting compliance\n\n9. QUERY STATUS:\n- Open queries reviewed\n- Aging queries addressed\n- Resolution tracking",
    "char_count": 458,
    "word_count": 67,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-002",
      "category": "monitoring",
      "title": "Monitoring Visit Report Requirements",
      "keywords": [
        "monitoring report",
        "visit report",
        "documentation",
        "CRA",
        "findings"
      ],
      "related_sections": [
        "MO-001",
        "ES-001",
        "DQ-003"
      ],
      "section_title": "REPORT SECTIONS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_7ea4fee0b4d0",
    "chunk_index": 2,
    "text": "9. QUERY STATUS:\n- Open queries reviewed\n- Aging queries addressed\n- Resolution tracking\n\n10. ACTION ITEMS:\n- Items from current visit\n- Items from previous visits\n- Responsible parties\n- Due dates",
    "char_count": 197,
    "word_count": 33,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "MO-002",
      "category": "monitoring",
      "title": "Monitoring Visit Report Requirements",
      "keywords": [
        "monitoring report",
        "visit report",
        "documentation",
        "CRA",
        "findings"
      ],
      "related_sections": [
        "MO-001",
        "ES-001",
        "DQ-003"
      ],
      "section_title": "REPORT SECTIONS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_697d19c20ed7",
    "chunk_index": 0,
    "text": "PERFORMANCE METRICS\n\nEnrollment Metrics:\n- Enrollment rate (subjects/month)\n- Screen failure rate\n- Randomization rate\n- Time to first enrollment\n\nData Quality Metrics:\n- DQI score (composite)\n- Query rate per subject\n- Query aging\n- Missing data rate\n\nCompliance Metrics:\n- Protocol deviation rate\n- SAE reporting compliance\n- Visit window compliance\n- Document submission timeliness\n\nOperational Metrics:\n- CRF completion time\n- Query response time\n- Signature turnaround\n- Staff turnover",
    "char_count": 490,
    "word_count": 73,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SI-001",
      "category": "site_management",
      "title": "Site Performance Assessment",
      "keywords": [
        "site performance",
        "metrics",
        "assessment",
        "benchmarking",
        "improvement"
      ],
      "related_sections": [
        "SI-002",
        "MO-001",
        "DQ-001"
      ],
      "section_title": "PERFORMANCE METRICS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_453ff3b20a8e",
    "chunk_index": 1,
    "text": "PERFORMANCE TIERS\n\nExceptional (Top 10%):\n- Benchmark site\n- Potential for increased enrollment\n- Reduced monitoring frequency\n\nStrong (70-90th percentile):\n- Meeting expectations\n- Standard monitoring\n- Minor improvement opportunities\n\nAverage (30-70th percentile):\n- Acceptable performance\n- Some attention needed\n- Standard monitoring\n\nBelow Average (10-30th percentile):\n- Needs improvement\n- Enhanced monitoring\n- Action plan required\n\nNeeds Improvement (Bottom 10%):\n- Significant concerns\n- Intensive monitoring\n- Remediation required\n- Potential for closure",
    "char_count": 565,
    "word_count": 74,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SI-001",
      "category": "site_management",
      "title": "Site Performance Assessment",
      "keywords": [
        "site performance",
        "metrics",
        "assessment",
        "benchmarking",
        "improvement"
      ],
      "related_sections": [
        "SI-002",
        "MO-001",
        "DQ-001"
      ],
      "section_title": "PERFORMANCE TIERS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_7e1ea3471e78",
    "chunk_index": 0,
    "text": "LEVEL 1: CRA MANAGEMENT (Days 1-7)\nTriggers:\n- Minor data quality issues\n- Routine query aging\n- Minor compliance gaps\n\nActions:\n- Document in visit report\n- Discuss with site coordinator\n- Provide training if needed\n- Set resolution timeline\n\nLEVEL 2: CTM INVOLVEMENT (Days 8-14)\nTriggers:\n- Persistent Level 1 issues\n- Moderate protocol deviations\n- Pattern of non-compliance\n\nActions:\n- CTM notified\n- Formal communication to site\n- Action plan development\n- Enhanced monitoring scheduled",
    "char_count": 491,
    "word_count": 77,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SI-002",
      "category": "site_management",
      "title": "Site Issue Escalation Procedures",
      "keywords": [
        "escalation",
        "site issues",
        "procedures",
        "levels",
        "remediation"
      ],
      "related_sections": [
        "SI-001",
        "MO-001",
        "PA-002"
      ],
      "section_title": "SITE ISSUE ESCALATION PROCEDURES\n\nESCALATION LEVELS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_e38433aa111c",
    "chunk_index": 1,
    "text": "LEVEL 3: STUDY LEAD ESCALATION (Days 15-21)\nTriggers:\n- Unresolved Level 2 issues\n- Major protocol deviations\n- Safety concerns\n- Significant data quality issues\n\nActions:\n- Study lead notification\n- Call with PI/site leadership\n- Written improvement plan\n- Timeline for resolution\n\nLEVEL 4: SPONSOR NOTIFICATION (Days 22-30)\nTriggers:\n- Critical safety issues\n- Persistent non-compliance\n- Data integrity concerns\n- Regulatory risk",
    "char_count": 432,
    "word_count": 64,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SI-002",
      "category": "site_management",
      "title": "Site Issue Escalation Procedures",
      "keywords": [
        "escalation",
        "site issues",
        "procedures",
        "levels",
        "remediation"
      ],
      "related_sections": [
        "SI-001",
        "MO-001",
        "PA-002"
      ],
      "section_title": "SITE ISSUE ESCALATION PROCEDURES\n\nESCALATION LEVELS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_f805c90241c8",
    "chunk_index": 2,
    "text": "Actions:\n- Sponsor immediately notified\n- Formal warning letter\n- Remediation plan required\n- Consideration for site closure\n\nLEVEL 5: SITE CLOSURE CONSIDERATION (Day 30+)\nTriggers:\n- Failed remediation\n- Continued non-compliance\n- Subject safety at risk\n- Fraudulent behavior\n\nActions:\n- Site closure evaluation\n- Subject transfer planning\n- Regulatory notifications\n- Documentation complete",
    "char_count": 392,
    "word_count": 55,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "SI-002",
      "category": "site_management",
      "title": "Site Issue Escalation Procedures",
      "keywords": [
        "escalation",
        "site issues",
        "procedures",
        "levels",
        "remediation"
      ],
      "related_sections": [
        "SI-001",
        "MO-001",
        "PA-002"
      ],
      "section_title": "SITE ISSUE ESCALATION PROCEDURES\n\nESCALATION LEVELS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_82d9ce6274c8",
    "chunk_index": 0,
    "text": "The Trial Master File contains essential documents that individually and collectively permit evaluation of trial conduct and data quality.\n\nTMF STRUCTURE (ICH E6 Section 8):\n\n1. PRE-STUDY DOCUMENTS:\n- Investigator's Brochure\n- Protocol and amendments\n- Informed consent forms\n- IRB/IEC approvals\n- Regulatory submissions\n- Insurance documentation\n- Investigator agreements\n- Financial disclosures",
    "char_count": 396,
    "word_count": 54,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-001",
      "category": "essential_documents",
      "title": "Trial Master File Requirements",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "regulatory"
      ],
      "related_sections": [
        "ES-002",
        "MO-002",
        "AU-001"
      ],
      "section_title": "TRIAL MASTER FILE (TMF) REQUIREMENTS\n\nTMF DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_238028178709",
    "chunk_index": 1,
    "text": "2. DURING TRIAL DOCUMENTS:\n- Monitoring visit reports\n- Communications (sponsor-site)\n- Updated IB versions\n- Protocol amendments\n- Consent form revisions\n- SAE reports\n- Protocol deviation reports\n- Subject enrollment logs\n\n3. POST-TRIAL DOCUMENTS:\n- Study closure notification\n- Final monitoring report\n- Drug accountability records\n- Final IRB/IEC notification\n- Clinical study report",
    "char_count": 387,
    "word_count": 56,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-001",
      "category": "essential_documents",
      "title": "Trial Master File Requirements",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "regulatory"
      ],
      "related_sections": [
        "ES-002",
        "MO-002",
        "AU-001"
      ],
      "section_title": "TRIAL MASTER FILE (TMF) REQUIREMENTS\n\nTMF DEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_e6a469d5acbd",
    "chunk_index": 2,
    "text": "TMF QUALITY STANDARDS\n\n- Complete: All required documents present\n- Accurate: Documents reflect actual events\n- Contemporaneous: Created at time of activity\n- Legible: Readable and clear\n- Attributable: Author/date identifiable",
    "char_count": 227,
    "word_count": 31,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-001",
      "category": "essential_documents",
      "title": "Trial Master File Requirements",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "regulatory"
      ],
      "related_sections": [
        "ES-002",
        "MO-002",
        "AU-001"
      ],
      "section_title": "TMF QUALITY STANDARDS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_253ba91bc341",
    "chunk_index": 3,
    "text": "TMF INSPECTION READINESS\n\nRequired state:\n- All documents filed\n- Index current\n- Cross-references complete\n- Filing consistent\n- Archive-ready\n\nCommon deficiencies:\n- Missing documents\n- Unsigned documents\n- Misfiled documents\n- Outdated versions\n- Incomplete filing\n\neTMF CONSIDERATIONS:\n- Validated system required\n- Audit trail maintained\n- Access controls in place\n- Backup procedures documented\n- 21 CFR Part 11 compliance",
    "char_count": 428,
    "word_count": 62,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-001",
      "category": "essential_documents",
      "title": "Trial Master File Requirements",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "regulatory"
      ],
      "related_sections": [
        "ES-002",
        "MO-002",
        "AU-001"
      ],
      "section_title": "TMF INSPECTION READINESS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a07d87e00c7b",
    "chunk_index": 0,
    "text": "DOCUMENT RETENTION REQUIREMENTS\n\nREGULATORY REQUIREMENTS\n\nICH E6 (R2):\n- Investigator: 2 years after last marketing approval or 2 years after formal discontinuation\n- Sponsor: Same as investigator requirements\n\nFDA (21 CFR 312.62):\n- 2 years following marketing application approval\n- If no application filed: 2 years after investigation discontinued\n\nEMA:\n- 15 years after study completion (clinical trial regulation)\n- Previous directive: 15 years minimum",
    "char_count": 457,
    "word_count": 65,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-002",
      "category": "essential_documents",
      "title": "Document Retention Requirements",
      "keywords": [
        "retention",
        "archiving",
        "documents",
        "regulatory requirements",
        "storage"
      ],
      "related_sections": [
        "ES-001",
        "AU-001",
        "RE-001"
      ],
      "section_title": "DOCUMENT RETENTION REQUIREMENTS\n\nREGULATORY REQUIREMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_f0e1cd6103dc",
    "chunk_index": 1,
    "text": "RETENTION CATEGORIES\n\nEssential Documents:\n- Protocol and amendments\n- Informed consents (signed)\n- IRB/IEC documentation\n- Regulatory submissions\n- AE/SAE reports\n- CRFs and source data\n- Monitoring reports\n- Drug accountability\n\nSupporting Documents:\n- Correspondence\n- Meeting minutes\n- Training records\n- CVs and delegation logs\n- Lab certifications",
    "char_count": 353,
    "word_count": 50,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-002",
      "category": "essential_documents",
      "title": "Document Retention Requirements",
      "keywords": [
        "retention",
        "archiving",
        "documents",
        "regulatory requirements",
        "storage"
      ],
      "related_sections": [
        "ES-001",
        "AU-001",
        "RE-001"
      ],
      "section_title": "RETENTION CATEGORIES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_f17a93f62960",
    "chunk_index": 2,
    "text": "RETENTION BEST PRACTICES\n\n1. Identify applicable requirements\n2. Apply longest retention period\n3. Document retention decisions\n4. Implement secure storage\n5. Plan for archive transfer\n6. Establish destruction procedures",
    "char_count": 220,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "ES-002",
      "category": "essential_documents",
      "title": "Document Retention Requirements",
      "keywords": [
        "retention",
        "archiving",
        "documents",
        "regulatory requirements",
        "storage"
      ],
      "related_sections": [
        "ES-001",
        "AU-001",
        "RE-001"
      ],
      "section_title": "RETENTION BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_836184a3d783",
    "chunk_index": 0,
    "text": "DEPENDENCY RELATIONSHIPS\n\nIssues often block resolution of downstream issues:\n\nMissing Visits  Missing Pages  Open Queries  SDV Pending  Signatures\n\nExample cascade:\n1. Missing visit creates missing pages\n2. Missing pages generate queries\n3. Queries block SDV completion\n4. SDV blocks signature\n5. Signature blocks DB lock",
    "char_count": 326,
    "word_count": 49,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "DEPENDENCY RELATIONSHIPS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_1dbb76411a63",
    "chunk_index": 1,
    "text": "UNLOCK SCORE CALCULATION\n\nPageRank-based algorithm assigns scores:\n- Higher score = More downstream impact\n- Resolving high-score issues unlocks more progress\n\nUnlock scores (typical):\n- Missing Visits: 100.0 (highest impact)\n- Missing Pages: 100.0\n- SAE-DM Pending: 73.5\n- Open Queries: 46.5\n- SAE-Safety: 39.7\n- SDV Pending: 37.2\n- Unsigned CRFs: 31.8",
    "char_count": 353,
    "word_count": 53,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "UNLOCK SCORE CALCULATION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_5d7f76ea0f7c",
    "chunk_index": 2,
    "text": "CASCADE NARRATIVES\n\nNatural language explanations:\n\"Fix Missing Visits (1) at Site_177\n Unlocks Missing Pages  Unlocks Queries  Unlocks SDV\n Net impact: 8 downstream issues resolved\"",
    "char_count": 186,
    "word_count": 28,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "CASCADE NARRATIVES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_f477a0543b7b",
    "chunk_index": 3,
    "text": "PRIORITIZATION STRATEGY\n\n1. Identify issues with highest unlock scores\n2. Group by responsible party\n3. Calculate effort vs. impact ratio\n4. Prioritize high-impact, low-effort items\n5. Execute in dependency order",
    "char_count": 212,
    "word_count": 30,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "PRIORITIZATION STRATEGY",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_9b0e89cf0c8c",
    "chunk_index": 4,
    "text": "CASCADE CLUSTERS\n\nGroup patients by issue combination:\n- Only SDV Pending (simple fix)\n- Missing + Queries (cascade)\n- SAE + SDV (safety + monitoring)\n- Complex (4+ issues)",
    "char_count": 172,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "CASCADE CLUSTERS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a24bea4459e5",
    "chunk_index": 5,
    "text": "BEST PRACTICES\n\n1. Always analyze cascades before prioritizing\n2. Don't fix downstream issues first\n3. Consider responsible parties\n4. Track cascade resolution\n5. Update priorities as issues resolve",
    "char_count": 198,
    "word_count": 28,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-001",
      "category": "cascade_analysis",
      "title": "Cascade Intelligence Methodology",
      "keywords": [
        "cascade",
        "dependencies",
        "unlock score",
        "prioritization",
        "impact analysis"
      ],
      "related_sections": [
        "CA-002",
        "DQ-001",
        "CL-002"
      ],
      "section_title": "BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_2c6cf6563bb0",
    "chunk_index": 0,
    "text": "IDENTIFYING CRITICAL PATH\n\n1. Map all blocking issues\n2. Identify dependencies\n3. Calculate resolution time for each\n4. Find longest dependent chain\n5. This chain is the critical path",
    "char_count": 183,
    "word_count": 29,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-002",
      "category": "cascade_analysis",
      "title": "Critical Path to Database Lock",
      "keywords": [
        "critical path",
        "timeline",
        "optimization",
        "database lock",
        "projection"
      ],
      "related_sections": [
        "CA-001",
        "DB-001",
        "SI-001"
      ],
      "section_title": "IDENTIFYING CRITICAL PATH",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_1be48e1b5c66",
    "chunk_index": 1,
    "text": "CRITICAL PATH COMPONENTS\n\nTypical critical path:\nMissing Data  Queries  SDV  Signatures  Lock\n\nTime estimates:\n- Missing Data: 2-5 days (site response)\n- Query Resolution: 3-7 days (back and forth)\n- SDV Completion: 1-3 days (CRA visit)\n- Signatures: 1-2 days (PI availability)\n- Lock Execution: 1 day",
    "char_count": 305,
    "word_count": 51,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-002",
      "category": "cascade_analysis",
      "title": "Critical Path to Database Lock",
      "keywords": [
        "critical path",
        "timeline",
        "optimization",
        "database lock",
        "projection"
      ],
      "related_sections": [
        "CA-001",
        "DB-001",
        "SI-001"
      ],
      "section_title": "CRITICAL PATH COMPONENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_b49d2e1f8610",
    "chunk_index": 2,
    "text": "CRITICAL PATH OPTIMIZATION\n\nParallel Processing:\n- Work on independent paths simultaneously\n- Assign different resources to different paths\n- Reduce overall timeline\n\nResource Prioritization:\n- Focus resources on critical path items\n- Non-critical items can wait\n- Avoid context switching\n\nBottleneck Resolution:\n- Identify slowest step\n- Add resources if possible\n- Remove dependencies if possible",
    "char_count": 398,
    "word_count": 56,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "CA-002",
      "category": "cascade_analysis",
      "title": "Critical Path to Database Lock",
      "keywords": [
        "critical path",
        "timeline",
        "optimization",
        "database lock",
        "projection"
      ],
      "related_sections": [
        "CA-001",
        "DB-001",
        "SI-001"
      ],
      "section_title": "CRITICAL PATH OPTIMIZATION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_0f93db472158",
    "chunk_index": 0,
    "text": "1. COORDINATOR OVERLOAD (PAT-RC-001)\nDetection: >30 subjects per coordinator\nImpact: Quality decline, delayed data entry\nIndicators:\n- Increased query rate\n- Longer CRF completion times\n- Missing data increase\nResolution: Add coordinator support\n\n2. PI ABSENCE CASCADE (PAT-TL-001)\nDetection: No signatures for 7+ days\nImpact: Signature backlog, lock delays\nIndicators:\n- Overdue signature count\n- Broken signature rate\n- Site inactivity\nResolution: Batch signature session, delegate",
    "char_count": 483,
    "word_count": 66,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-001",
      "category": "patterns",
      "title": "Known Issue Patterns",
      "keywords": [
        "patterns",
        "recognition",
        "detection",
        "coordinator overload",
        "PI absence"
      ],
      "related_sections": [
        "PA-002",
        "AN-001",
        "SI-001"
      ],
      "section_title": "VALIDATED PATTERNS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_5feae1ce8b3a",
    "chunk_index": 1,
    "text": "3. NEW SITE RAMP PATTERN\nDetection: First 60 days after activation\nImpact: Higher query rate, protocol deviations\nIndicators:\n- Query rate 2x average\n- Training gaps evident\n- Documentation issues\nResolution: Enhanced support, re-training\n\n4. END-OF-MONTH RUSH\nDetection: Last week of month spike\nImpact: Data quality dip\nIndicators:\n- Bulk data entry\n- Increased errors\n- Resource strain\nResolution: Stagger deadlines, daily entry emphasis",
    "char_count": 440,
    "word_count": 64,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-001",
      "category": "patterns",
      "title": "Known Issue Patterns",
      "keywords": [
        "patterns",
        "recognition",
        "detection",
        "coordinator overload",
        "PI absence"
      ],
      "related_sections": [
        "PA-002",
        "AN-001",
        "SI-001"
      ],
      "section_title": "VALIDATED PATTERNS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_61c77b19ea2b",
    "chunk_index": 2,
    "text": "5. QUERY PING-PONG\nDetection: Same query re-opened 3+ times\nImpact: Resolution delays\nIndicators:\n- High re-open rate\n- Incomplete responses\n- Frustration\nResolution: Phone resolution, clarification\n\n6. SDV BACKLOG\nDetection: >100 CRFs pending SDV\nImpact: Lock timeline risk\nIndicators:\n- SDV rate declining\n- Visit gaps\n- CRA resource constraints\nResolution: Additional monitoring visits",
    "char_count": 388,
    "word_count": 54,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-001",
      "category": "patterns",
      "title": "Known Issue Patterns",
      "keywords": [
        "patterns",
        "recognition",
        "detection",
        "coordinator overload",
        "PI absence"
      ],
      "related_sections": [
        "PA-002",
        "AN-001",
        "SI-001"
      ],
      "section_title": "VALIDATED PATTERNS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_e47d60b07d09",
    "chunk_index": 3,
    "text": "PATTERN RESPONSE\n\n1. Detection: Pattern match identified\n2. Verification: Confirm pattern applies\n3. Alert: Notify responsible parties\n4. Action: Implement resolution\n5. Monitor: Track effectiveness",
    "char_count": 198,
    "word_count": 25,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-001",
      "category": "patterns",
      "title": "Known Issue Patterns",
      "keywords": [
        "patterns",
        "recognition",
        "detection",
        "coordinator overload",
        "PI absence"
      ],
      "related_sections": [
        "PA-002",
        "AN-001",
        "SI-001"
      ],
      "section_title": "PATTERN RESPONSE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_316c6a480f53",
    "chunk_index": 0,
    "text": "ANOMALY DETECTION METHODS\n\nStatistical Methods:\n- Z-score analysis (>2 from mean)\n- Interquartile range (IQR)\n- Percentile thresholds (P95, P99)\n\nMachine Learning:\n- Isolation Forest\n- Local Outlier Factor (LOF)\n- Autoencoder reconstruction error\n\nPattern-Based:\n- Unusual data entry times\n- Digit preference\n- Value clustering",
    "char_count": 328,
    "word_count": 46,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-002",
      "category": "patterns",
      "title": "Anomaly Detection and Response",
      "keywords": [
        "anomaly",
        "detection",
        "outlier",
        "investigation",
        "fraud",
        "data integrity"
      ],
      "related_sections": [
        "PA-001",
        "DQ-001",
        "SA-002"
      ],
      "section_title": "ANOMALY DETECTION METHODS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_4d7f6a4dd852",
    "chunk_index": 1,
    "text": "ANOMALY CATEGORIES\n\nPatient-Level:\n- Unusual data patterns for individual subject\n- Inconsistent data across visits\n- Extreme values\n\nSite-Level:\n- Different patterns from peer sites\n- Unusual enrollment patterns\n- Homogeneous data\n\nStudy-Level:\n- Regional differences\n- Temporal trends\n- Emerging safety signals",
    "char_count": 312,
    "word_count": 43,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-002",
      "category": "patterns",
      "title": "Anomaly Detection and Response",
      "keywords": [
        "anomaly",
        "detection",
        "outlier",
        "investigation",
        "fraud",
        "data integrity"
      ],
      "related_sections": [
        "PA-001",
        "DQ-001",
        "SA-002"
      ],
      "section_title": "ANOMALY CATEGORIES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_95b12a6f83df",
    "chunk_index": 2,
    "text": "ANOMALY SEVERITY\n\nCritical (P99+): 1% most extreme\n- Immediate investigation required\n- Potential data integrity issue\n- Possible fraud indicator\n\nHigh (P95-P99): 4% next most extreme\n- Investigation within 48 hours\n- Enhanced monitoring needed\n- Root cause analysis\n\nMedium (P90-P95): 5% next\n- Review at next visit\n- Document explanation\n- Monitor for trends\n\nLow (<P90): Within normal variation\n- No action required\n- Monitor if recurring",
    "char_count": 441,
    "word_count": 68,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-002",
      "category": "patterns",
      "title": "Anomaly Detection and Response",
      "keywords": [
        "anomaly",
        "detection",
        "outlier",
        "investigation",
        "fraud",
        "data integrity"
      ],
      "related_sections": [
        "PA-001",
        "DQ-001",
        "SA-002"
      ],
      "section_title": "ANOMALY SEVERITY",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_d98f0b00bb39",
    "chunk_index": 3,
    "text": "INVESTIGATION PROCESS\n\n1. Detection: Anomaly flagged by system\n2. Verification: Confirm anomaly is real\n3. Investigation: Root cause analysis\n4. Documentation: Record findings\n5. Resolution: Address if valid issue\n6. Monitoring: Track for recurrence",
    "char_count": 249,
    "word_count": 34,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "PA-002",
      "category": "patterns",
      "title": "Anomaly Detection and Response",
      "keywords": [
        "anomaly",
        "detection",
        "outlier",
        "investigation",
        "fraud",
        "data integrity"
      ],
      "related_sections": [
        "PA-001",
        "DQ-001",
        "SA-002"
      ],
      "section_title": "INVESTIGATION PROCESS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_4453da676500",
    "chunk_index": 0,
    "text": "OVERVIEW\n\n21 CFR Part 11 establishes FDA requirements for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records.",
    "char_count": 175,
    "word_count": 24,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "RE-001",
      "category": "regulatory",
      "title": "21 CFR Part 11 Compliance",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "audit trail",
        "compliance",
        "FDA"
      ],
      "related_sections": [
        "RE-002",
        "ES-001",
        "AU-001"
      ],
      "section_title": "OVERVIEW",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_76eace9428ce",
    "chunk_index": 1,
    "text": "KEY REQUIREMENTS\n\n1. VALIDATION (11.10(a)):\n- Systems must be validated\n- Intended use established\n- Validation documented\n\n2. AUDIT TRAILS (11.10(e)):\n- Computer-generated\n- Time-stamped\n- Independent of operator\n- Cannot be modified\n\n3. ACCESS CONTROLS (11.10(d)):\n- Limiting system access\n- Authority levels defined\n- User-specific accounts\n- Automatic logoff\n\n4. ELECTRONIC SIGNATURES (11.100):\n- Unique to individual\n- Not reused or reassigned\n- Two components (ID + password)\n- Linked to electronic record\n\n5. SIGNATURE MANIFESTATIONS (11.50):\n- Name of signer\n- Date and time\n- Meaning (approval, review, etc.)\n\n6. SIGNATURE LINKING (11.70):\n- Signatures linked to records\n- Cannot be copied/transferred\n- Invalidation detectable",
    "char_count": 742,
    "word_count": 108,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "RE-001",
      "category": "regulatory",
      "title": "21 CFR Part 11 Compliance",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "audit trail",
        "compliance",
        "FDA"
      ],
      "related_sections": [
        "RE-002",
        "ES-001",
        "AU-001"
      ],
      "section_title": "KEY REQUIREMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_7a14627a9e49",
    "chunk_index": 2,
    "text": "TRIALPULSE COMPLIANCE\n\nAudit Trail:\n- All data changes logged\n- User, timestamp, old/new values\n- Immutable log (append-only)\n- Exportable for inspection\n\nAccess Control:\n- Role-based access\n- User authentication\n- Session management\n- Privilege verification\n\nData Integrity:\n- Input validation\n- Checksums\n- Backup procedures\n- Recovery testing",
    "char_count": 345,
    "word_count": 49,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "RE-001",
      "category": "regulatory",
      "title": "21 CFR Part 11 Compliance",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "audit trail",
        "compliance",
        "FDA"
      ],
      "related_sections": [
        "RE-002",
        "ES-001",
        "AU-001"
      ],
      "section_title": "TRIALPULSE COMPLIANCE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_910a589062da",
    "chunk_index": 0,
    "text": "LAWFUL BASIS FOR PROCESSING\n\nClinical trials typically rely on:\n- Consent (informed consent for trial participation)\n- Legal obligation (regulatory requirements)\n- Scientific research exemption (with safeguards)",
    "char_count": 211,
    "word_count": 27,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "RE-002",
      "category": "regulatory",
      "title": "GDPR and Privacy Considerations",
      "keywords": [
        "GDPR",
        "privacy",
        "data protection",
        "consent",
        "pseudonymization"
      ],
      "related_sections": [
        "RE-001",
        "ES-002",
        "AU-001"
      ],
      "section_title": "LAWFUL BASIS FOR PROCESSING",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_82d37f7af74c",
    "chunk_index": 1,
    "text": "KEY GDPR PRINCIPLES\n\n1. Lawfulness, Fairness, Transparency\n- Clear communication about data use\n- Legitimate basis for processing\n- Accessible privacy notices\n\n2. Purpose Limitation\n- Data collected for specified purposes\n- No incompatible secondary use\n- Research exemption may apply\n\n3. Data Minimization\n- Only necessary data collected\n- Avoid excessive data collection\n- Regular review of data needs\n\n4. Accuracy\n- Data kept up to date\n- Correction mechanisms in place\n- Verification procedures\n\n5. Storage Limitation\n- Defined retention periods\n- Deletion when no longer needed\n- Research exemption considerations\n\n6. Security\n- Appropriate technical measures\n- Organizational safeguards\n- Breach notification procedures",
    "char_count": 725,
    "word_count": 106,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "RE-002",
      "category": "regulatory",
      "title": "GDPR and Privacy Considerations",
      "keywords": [
        "GDPR",
        "privacy",
        "data protection",
        "consent",
        "pseudonymization"
      ],
      "related_sections": [
        "RE-001",
        "ES-002",
        "AU-001"
      ],
      "section_title": "KEY GDPR PRINCIPLES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a850d28ef253",
    "chunk_index": 0,
    "text": "AUDIT TRAIL REQUIREMENTS\n\nDEFINITION\n\nAn audit trail is a secure, computer-generated, time-stamped record that allows reconstruction of events relating to creation, modification, or deletion of electronic records.",
    "char_count": 213,
    "word_count": 27,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-001",
      "category": "audit",
      "title": "Audit Trail Requirements",
      "keywords": [
        "audit trail",
        "logging",
        "traceability",
        "regulatory",
        "changes"
      ],
      "related_sections": [
        "AU-002",
        "RE-001",
        "ES-001"
      ],
      "section_title": "AUDIT TRAIL REQUIREMENTS\n\nDEFINITION",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_58b13620853f",
    "chunk_index": 1,
    "text": "REGULATORY REQUIREMENTS\n\nFDA (21 CFR 11.10(e)):\n- Computer-generated, time-stamped\n- Independent of system operators\n- Available for regulatory review\n- Record any changes to data\n\nEMA (Annex 11):\n- All GxP relevant changes recorded\n- Previous values available\n- Reason for change documented\n- User and timestamp recorded",
    "char_count": 321,
    "word_count": 48,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-001",
      "category": "audit",
      "title": "Audit Trail Requirements",
      "keywords": [
        "audit trail",
        "logging",
        "traceability",
        "regulatory",
        "changes"
      ],
      "related_sections": [
        "AU-002",
        "RE-001",
        "ES-001"
      ],
      "section_title": "REGULATORY REQUIREMENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_805eeee5812a",
    "chunk_index": 2,
    "text": "AUDIT TRAIL COMPONENTS\n\nWhat to capture:\n- User ID\n- Date and time\n- Action performed\n- Old value\n- New value\n- Reason for change (where applicable)\n\nActions to log:\n- Create\n- Read (for sensitive data)\n- Update\n- Delete\n- Sign\n- Approve\n- Login/logout",
    "char_count": 252,
    "word_count": 48,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-001",
      "category": "audit",
      "title": "Audit Trail Requirements",
      "keywords": [
        "audit trail",
        "logging",
        "traceability",
        "regulatory",
        "changes"
      ],
      "related_sections": [
        "AU-002",
        "RE-001",
        "ES-001"
      ],
      "section_title": "AUDIT TRAIL COMPONENTS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_957f7858983c",
    "chunk_index": 3,
    "text": "AUDIT TRAIL BEST PRACTICES\n\n1. Immutability\n- Append-only log\n- Cannot modify entries\n- Tamper-evident\n\n2. Completeness\n- All changes captured\n- No gaps in record\n- Includes system events\n\n3. Accessibility\n- Easily exportable\n- Human-readable format\n- Available for inspection\n\n4. Review\n- Regular audit trail review\n- Documented review process\n- Anomaly investigation",
    "char_count": 368,
    "word_count": 56,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-001",
      "category": "audit",
      "title": "Audit Trail Requirements",
      "keywords": [
        "audit trail",
        "logging",
        "traceability",
        "regulatory",
        "changes"
      ],
      "related_sections": [
        "AU-002",
        "RE-001",
        "ES-001"
      ],
      "section_title": "AUDIT TRAIL BEST PRACTICES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_425a77f55c97",
    "chunk_index": 4,
    "text": "TRIALPULSE AUDIT TRAIL\n\nCaptures:\n- All data changes\n- User actions\n- Agent recommendations\n- Human decisions\n- Override reasons\n\nFormat:\n- Timestamp (ISO 8601)\n- User/Agent ID\n- Action type\n- Entity affected\n- Before/after values\n- Reasoning (for AI actions)\n\nExport:\n- JSON format\n- CSV format\n- Regulatory format\n- Date range filtering",
    "char_count": 338,
    "word_count": 56,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-001",
      "category": "audit",
      "title": "Audit Trail Requirements",
      "keywords": [
        "audit trail",
        "logging",
        "traceability",
        "regulatory",
        "changes"
      ],
      "related_sections": [
        "AU-002",
        "RE-001",
        "ES-001"
      ],
      "section_title": "TRIALPULSE AUDIT TRAIL",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_f6ed906d7f8d",
    "chunk_index": 0,
    "text": "INSPECTION PREPARATION GUIDE\n\nINSPECTION TYPES\n\nFDA Inspection:\n- Pre-approval (pre-NDA/BLA)\n- Routine surveillance\n- For-cause investigation\n- BIMO (Bioresearch Monitoring)\n\nEMA Inspection:\n- GCP inspection\n- Pharmacovigilance inspection\n- GMP inspection\n\nSponsor Audit:\n- Internal quality audits\n- CRO oversight audits\n- Vendor audits",
    "char_count": 336,
    "word_count": 44,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-002",
      "category": "audit",
      "title": "Inspection Preparation Guide",
      "keywords": [
        "inspection",
        "preparation",
        "FDA",
        "audit",
        "readiness",
        "CAPA"
      ],
      "related_sections": [
        "AU-001",
        "ES-001",
        "RE-001"
      ],
      "section_title": "INSPECTION PREPARATION GUIDE\n\nINSPECTION TYPES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_ef2ed48dc4dd",
    "chunk_index": 1,
    "text": "KEY DOCUMENTS TO PREPARE\n\n1. Protocol and amendments\n2. IRB/IEC approvals\n3. Informed consent forms\n4. Investigator CVs and logs\n5. Monitoring reports\n6. SAE reports\n7. Protocol deviations\n8. Drug accountability",
    "char_count": 211,
    "word_count": 32,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-002",
      "category": "audit",
      "title": "Inspection Preparation Guide",
      "keywords": [
        "inspection",
        "preparation",
        "FDA",
        "audit",
        "readiness",
        "CAPA"
      ],
      "related_sections": [
        "AU-001",
        "ES-001",
        "RE-001"
      ],
      "section_title": "KEY DOCUMENTS TO PREPARE",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_a4930699faef",
    "chunk_index": 2,
    "text": "INSPECTION DAY PROCEDURES\n\n1. Designate inspection point person\n2. Prepare inspection room\n3. Brief staff on process\n4. Document requests promptly\n5. Provide requested documents\n6. Note inspector questions\n7. Prepare daily summary",
    "char_count": 230,
    "word_count": 33,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-002",
      "category": "audit",
      "title": "Inspection Preparation Guide",
      "keywords": [
        "inspection",
        "preparation",
        "FDA",
        "audit",
        "readiness",
        "CAPA"
      ],
      "related_sections": [
        "AU-001",
        "ES-001",
        "RE-001"
      ],
      "section_title": "INSPECTION DAY PROCEDURES",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_1cbef4b96a5f",
    "chunk_index": 3,
    "text": "COMMON FINDINGS\n\n- Informed consent issues\n- Protocol deviations not reported\n- Source document discrepancies\n- AE/SAE reporting delays\n- Inadequate oversight\n- Missing essential documents",
    "char_count": 188,
    "word_count": 26,
    "metadata": {
      "source": "protocol",
      "source_name": "Protocol Knowledge Base",
      "document_type": "knowledge_base",
      "section_id": "AU-002",
      "category": "audit",
      "title": "Inspection Preparation Guide",
      "keywords": [
        "inspection",
        "preparation",
        "FDA",
        "audit",
        "readiness",
        "CAPA"
      ],
      "related_sections": [
        "AU-001",
        "ES-001",
        "RE-001"
      ],
      "section_title": "COMMON FINDINGS",
      "section_type": "header"
    }
  },
  {
    "chunk_id": "chunk_3a19dfbea77f",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for accurate and timely data entry and verification in clinical trials.\n\nSCOPE: This SOP applies to all clinical trial data entry personnel, data managers, and CRAs involved in data collection and verification.\n\n1. PURPOSE\nThis SOP describes the procedures for entering clinical trial data into the Electronic Data Capture (EDC) system and verifying data accuracy.\n\n2. RESPONSIBILITIES",
    "char_count": 420,
    "word_count": 61,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_027054c9f40b",
    "chunk_index": 1,
    "text": "2.1 Site Coordinator:\n- Enter data within 3 business days of subject visit\n- Respond to queries within 5 business days\n- Verify data accuracy against source documents\n- Obtain required signatures",
    "char_count": 195,
    "word_count": 32,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "2.1",
      "section_title": "Site Coordinator:",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8c28693a92bc",
    "chunk_index": 2,
    "text": "2.2 Data Manager:\n- Review data for completeness and consistency\n- Generate and manage data queries\n- Perform data validation checks\n- Track data entry metrics",
    "char_count": 159,
    "word_count": 26,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "2.2",
      "section_title": "Data Manager:",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_134b02b38c9b",
    "chunk_index": 3,
    "text": "2.3 CRA:\n- Perform source data verification\n- Identify data discrepancies\n- Document findings in monitoring reports\n- Follow up on outstanding issues\n\n3. PROCEDURES",
    "char_count": 164,
    "word_count": 25,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "2.3",
      "section_title": "CRA:",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_dfdad8c47f23",
    "chunk_index": 4,
    "text": "3.1 Data Entry\na) Log into EDC system with unique credentials\nb) Select appropriate subject and visit\nc) Enter all required data fields\nd) Review entries before saving\ne) Submit for query/review as applicable",
    "char_count": 208,
    "word_count": 34,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "3.1",
      "section_title": "Data Entry",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d4428b916a24",
    "chunk_index": 5,
    "text": "3.2 Data Verification\na) Compare EDC data to source documents\nb) Verify dates, values, and units\nc) Check for transcription errors\nd) Document any discrepancies\ne) Generate queries for corrections",
    "char_count": 196,
    "word_count": 30,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "3.2",
      "section_title": "Data Verification",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2077b78d0a57",
    "chunk_index": 6,
    "text": "3.3 Query Management\na) Review open queries daily\nb) Investigate data discrepancy\nc) Provide complete response with source reference\nd) Make corrections as appropriate\ne) Verify query closure",
    "char_count": 191,
    "word_count": 28,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "3.3",
      "section_title": "Query Management",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_11693efc974e",
    "chunk_index": 7,
    "text": "3.4 Timeline Requirements\n- Initial data entry: Within 3 business days of visit\n- Query response: Within 5 business days\n- SDV completion: Per monitoring plan\n- Signature completion: Within 7 business days\n\n4. QUALITY CONTROL\n- Weekly data entry compliance review\n- Monthly query aging analysis\n- Quarterly process review\n- Annual SOP review\n\n5. DOCUMENTATION\n- All entries logged in EDC audit trail\n- Query responses documented\n- SDV documented in monitoring reports\n- Training records maintained\n\n6. REFERENCES\n- ICH E6(R2) Section 4.9\n- 21 CFR Part 11\n- Company Data Management Plan",
    "char_count": 585,
    "word_count": 96,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-001",
      "title": "Data Entry and Verification Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "data entry",
        "verification",
        "EDC",
        "queries",
        "source documents"
      ],
      "roles": [
        "Site Coordinator",
        "Data Manager",
        "CRA"
      ],
      "section_number": "3.4",
      "section_title": "Timeline Requirements",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_dd72ec522cd5",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish standardized procedures for generating, tracking, and resolving data queries.\n\nSCOPE: This SOP applies to data managers, site coordinators, and CRAs involved in query management.\n\n1. PURPOSE\nThis SOP defines the procedures for managing data queries throughout the clinical trial lifecycle.\n\n2. QUERY TYPES",
    "char_count": 329,
    "word_count": 46,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_ba5869b319ee",
    "chunk_index": 1,
    "text": "2.3 Query Categories\n- DM Query: Data management issues\n- Clinical Query: Clinical/medical questions\n- Safety Query: Safety-related clarifications\n- Coding Query: Coding clarification needed\n\n3. PROCEDURES",
    "char_count": 205,
    "word_count": 27,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_number": "2.3",
      "section_title": "Query Categories",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_018e115f3990",
    "chunk_index": 2,
    "text": "3.1 Query Generation\na) Identify data discrepancy or question\nb) Verify discrepancy is valid\nc) Write clear, specific query text\nd) Select appropriate query type\ne) Assign to appropriate recipient\nf) Set priority level",
    "char_count": 218,
    "word_count": 34,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_number": "3.1",
      "section_title": "Query Generation",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_565d73991a67",
    "chunk_index": 3,
    "text": "3.2 Query Text Standards\n- Be specific about the issue\n- Reference the data in question\n- Ask a clear question\n- Avoid leading the response\n- Include source reference if applicable\n\nEXAMPLE:\n\"The reported lab value of 150 mg/dL for glucose on 15-Jan-2024 appears to be outside the expected range. Please verify this value against source documents and confirm or correct.\"",
    "char_count": 371,
    "word_count": 62,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_number": "3.2",
      "section_title": "Query Text Standards",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_71b7992a149a",
    "chunk_index": 4,
    "text": "3.3 Query Response\na) Review query details\nb) Check source documents\nc) Provide complete response\nd) Include source document reference\ne) Make corrections if needed\nf) Do not close query without resolution",
    "char_count": 205,
    "word_count": 32,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_number": "3.3",
      "section_title": "Query Response",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4634ee6ccc71",
    "chunk_index": 5,
    "text": "3.4 Query Escalation\n- Day 5: First reminder (auto-generated)\n- Day 10: CRA follow-up\n- Day 15: CTM notification\n- Day 21: Study Lead escalation\n- Day 30: Sponsor notification\n\n4. QUERY AGING CATEGORIES\n- Current (0-5 days): Normal processing\n- Aging (6-10 days): Attention needed\n- Overdue (11-20 days): Escalation triggered\n- Critical (>20 days): Immediate action required\n\n5. QUERY METRICS\n- Query rate per subject\n- Query resolution time\n- Query re-open rate\n- Queries by type/category\n- Aging distribution\n\n6. QUALITY CONTROL\n- Daily review of new queries\n- Weekly aging review\n- Monthly trend analysis\n- Quarterly process optimization",
    "char_count": 640,
    "word_count": 103,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-002",
      "title": "Query Generation and Resolution",
      "version": "2.5",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "query",
        "resolution",
        "escalation",
        "data clarification",
        "aging"
      ],
      "roles": [
        "Data Manager",
        "Site Coordinator",
        "CRA"
      ],
      "section_number": "3.4",
      "section_title": "Query Escalation",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a63663b28d20",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for preparing and executing clinical trial database lock.\n\nSCOPE: This SOP applies to data management, clinical operations, and biostatistics personnel involved in database lock activities.\n\n1. PURPOSE\nThis SOP describes the procedures for achieving database lock in clinical trials, ensuring data integrity and regulatory compliance.\n\n2. PRE-LOCK REQUIREMENTS",
    "char_count": 395,
    "word_count": 52,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-003",
      "title": "Database Lock Procedures",
      "version": "2.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "database lock",
        "freeze",
        "data integrity",
        "pre-lock",
        "post-lock"
      ],
      "roles": [
        "Data Manager",
        "Study Manager",
        "Biostatistician"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_95c12b46fd11",
    "chunk_index": 1,
    "text": "3.1 Pre-Lock Checklist\n Data entry complete\n All queries closed\n SDV 100% complete\n All signatures obtained\n Coding complete\n SAE reconciliation complete\n External data reconciled\n Medical review complete",
    "char_count": 212,
    "word_count": 34,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-003",
      "title": "Database Lock Procedures",
      "version": "2.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "database lock",
        "freeze",
        "data integrity",
        "pre-lock",
        "post-lock"
      ],
      "roles": [
        "Data Manager",
        "Study Manager",
        "Biostatistician"
      ],
      "section_number": "3.1",
      "section_title": "Pre-Lock Checklist",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_17e4f743757a",
    "chunk_index": 2,
    "text": "3.2 Lock Execution\na) Verify pre-lock checklist complete\nb) Obtain lock approvals\nc) Execute soft lock (freeze)\nd) Perform final data review\ne) Execute hard lock\nf) Generate lock documentation\ng) Archive database",
    "char_count": 212,
    "word_count": 33,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-003",
      "title": "Database Lock Procedures",
      "version": "2.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "database lock",
        "freeze",
        "data integrity",
        "pre-lock",
        "post-lock"
      ],
      "roles": [
        "Data Manager",
        "Study Manager",
        "Biostatistician"
      ],
      "section_number": "3.2",
      "section_title": "Lock Execution",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_65ba41ffe157",
    "chunk_index": 3,
    "text": "3.3 Lock Approvals Required\n- Data Management Lead\n- Medical Monitor\n- Biostatistics Lead\n- Study Manager\n- Sponsor Representative\n\n4. POST-LOCK PROCEDURES",
    "char_count": 155,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-003",
      "title": "Database Lock Procedures",
      "version": "2.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "database lock",
        "freeze",
        "data integrity",
        "pre-lock",
        "post-lock"
      ],
      "roles": [
        "Data Manager",
        "Study Manager",
        "Biostatistician"
      ],
      "section_number": "3.3",
      "section_title": "Lock Approvals Required",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4af538e7a746",
    "chunk_index": 4,
    "text": "4.2 Unlock Procedures (if needed)\n- Formal unlock request required\n- Reason documented\n- Limited scope unlock preferred\n- Re-lock with documentation\n\n5. TIMELINE\n- 4 weeks pre-lock: 80% subjects clean\n- 2 weeks pre-lock: 95% subjects clean\n- 1 week pre-lock: All subjects frozen\n- Lock day: Final lock execution\n- Post-lock: Analysis datasets created\n\n6. QUALITY CONTROL\n- Daily pre-lock status review\n- Lock readiness meetings\n- Post-lock verification\n- Documentation audit",
    "char_count": 474,
    "word_count": 74,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-DM-003",
      "title": "Database Lock Procedures",
      "version": "2.0",
      "department": "Data Management",
      "category": "data_management",
      "keywords": [
        "database lock",
        "freeze",
        "data integrity",
        "pre-lock",
        "post-lock"
      ],
      "roles": [
        "Data Manager",
        "Study Manager",
        "Biostatistician"
      ],
      "section_number": "4.2",
      "section_title": "Unlock Procedures (if needed)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0cd0102582e2",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for conducting clinical trial monitoring visits.\n\nSCOPE: This SOP applies to CRAs, CTMs, and clinical operations personnel involved in site monitoring.\n\n1. PURPOSE\nThis SOP describes the procedures for planning, conducting, and documenting clinical trial monitoring visits.\n\n2. MONITORING APPROACH",
    "char_count": 332,
    "word_count": 44,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-001",
      "title": "Site Monitoring Procedures",
      "version": "4.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring",
        "site visit",
        "CRA",
        "SDV",
        "risk-based monitoring"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_b59b2ac633bb",
    "chunk_index": 1,
    "text": "2.1 Risk-Based Monitoring\n- Centralized monitoring as primary method\n- On-site monitoring based on risk assessment\n- Targeted SDV for critical data\n- Key Risk Indicators (KRIs) tracking",
    "char_count": 185,
    "word_count": 28,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-001",
      "title": "Site Monitoring Procedures",
      "version": "4.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring",
        "site visit",
        "CRA",
        "SDV",
        "risk-based monitoring"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "2.1",
      "section_title": "Risk-Based Monitoring",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_2285c5eb6009",
    "chunk_index": 2,
    "text": "3.1 Planning\na) Review previous visit report\nb) Review centralized monitoring data\nc) Identify focus areas\nd) Schedule visit with site\ne) Prepare visit agenda\nf) Review outstanding action items",
    "char_count": 193,
    "word_count": 30,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-001",
      "title": "Site Monitoring Procedures",
      "version": "4.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring",
        "site visit",
        "CRA",
        "SDV",
        "risk-based monitoring"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "3.1",
      "section_title": "Planning",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0de123eef9f7",
    "chunk_index": 3,
    "text": "3.2 Pre-Visit Letter\n- Confirm date and time\n- List documents needed\n- Identify subjects for review\n- Request staff availability\n- Send 2 weeks in advance\n\n4. ON-SITE PROCEDURES",
    "char_count": 177,
    "word_count": 30,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-001",
      "title": "Site Monitoring Procedures",
      "version": "4.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring",
        "site visit",
        "CRA",
        "SDV",
        "risk-based monitoring"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "3.2",
      "section_title": "Pre-Visit Letter",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_04519a6198b0",
    "chunk_index": 4,
    "text": "5.2 Follow-up\n- Track action items\n- Provide support as needed\n- Escalate if issues persist\n\n6. SDV REQUIREMENTS\n- 100% for critical data points\n- Per monitoring plan for other data\n- Document in monitoring report\n- Generate queries for discrepancies",
    "char_count": 250,
    "word_count": 42,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-001",
      "title": "Site Monitoring Procedures",
      "version": "4.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring",
        "site visit",
        "CRA",
        "SDV",
        "risk-based monitoring"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "5.2",
      "section_title": "Follow-up",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_327d2afd527a",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for completing and distributing monitoring visit reports.\n\nSCOPE: This SOP applies to CRAs and CTMs responsible for monitoring report documentation.\n\n1. PURPOSE\nThis SOP describes the requirements for completing monitoring visit reports in a timely and comprehensive manner.\n\n2. REPORT TIMING\n- Draft completion: Within 5 business days\n- Final submission: Within 10 business days\n- Critical findings: Reported within 24 hours\n\n3. REPORT SECTIONS",
    "char_count": 480,
    "word_count": 69,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-002",
      "title": "Monitoring Report Completion",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring report",
        "documentation",
        "visit report",
        "findings",
        "action items"
      ],
      "roles": [
        "CRA",
        "CTM"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_82ad1d05b8b8",
    "chunk_index": 1,
    "text": "3.9 Action Items\n- Previous items status\n- New items identified\n- Responsible party\n- Due dates\n\n4. REPORT QUALITY\n- Clear, factual language\n- No opinions without evidence\n- Consistent with previous reports\n- Proofread before submission\n\n5. REPORT DISTRIBUTION\n- Sponsor/CRO\n- TMF\n- Site file (if required)\n- Regulatory file\n\n6. ARCHIVING\n- Part of Trial Master File\n- Retained per retention requirements\n- Available for audit/inspection",
    "char_count": 437,
    "word_count": 70,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-002",
      "title": "Monitoring Report Completion",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "monitoring report",
        "documentation",
        "visit report",
        "findings",
        "action items"
      ],
      "roles": [
        "CRA",
        "CTM"
      ],
      "section_number": "3.9",
      "section_title": "Action Items",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d86e893b8e9a",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for conducting centralized monitoring activities.\n\nSCOPE: This SOP applies to data managers, CRAs, and clinical operations personnel involved in centralized monitoring.\n\n1. PURPOSE\nThis SOP describes the procedures for conducting centralized monitoring as part of a risk-based monitoring approach.\n\n2. CENTRALIZED MONITORING COMPONENTS",
    "char_count": 370,
    "word_count": 47,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-003",
      "title": "Centralized Monitoring Procedures",
      "version": "2.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "centralized monitoring",
        "KRI",
        "risk indicators",
        "remote monitoring",
        "analytics"
      ],
      "roles": [
        "Data Manager",
        "CRA",
        "CTM"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_21525f47f816",
    "chunk_index": 1,
    "text": "5.2 Centralized Monitoring Report\n- Monthly summary\n- Site-specific findings\n- Recommended actions\n- Trend analysis\n\n6. INTEGRATION WITH ON-SITE MONITORING\n- Inform visit planning\n- Focus areas for SDV\n- Guide resource allocation\n- Support risk assessment",
    "char_count": 255,
    "word_count": 38,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-MO-003",
      "title": "Centralized Monitoring Procedures",
      "version": "2.0",
      "department": "Clinical Operations",
      "category": "monitoring",
      "keywords": [
        "centralized monitoring",
        "KRI",
        "risk indicators",
        "remote monitoring",
        "analytics"
      ],
      "roles": [
        "Data Manager",
        "CRA",
        "CTM"
      ],
      "section_number": "5.2",
      "section_title": "Centralized Monitoring Report",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_10eee50d5df2",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for reporting serious adverse events in clinical trials.\n\nSCOPE: This SOP applies to all personnel involved in SAE identification, documentation, and reporting.\n\n1. PURPOSE\nThis SOP describes the procedures for identifying, documenting, and reporting serious adverse events (SAEs) in clinical trials.",
    "char_count": 335,
    "word_count": 45,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_42cea40ea194",
    "chunk_index": 1,
    "text": "2. SAE DEFINITION\nA Serious Adverse Event is any untoward medical occurrence that:\n- Results in death\n- Is life-threatening\n- Requires inpatient hospitalization or prolongs existing hospitalization\n- Results in persistent or significant disability/incapacity\n- Is a congenital anomaly/birth defect\n- Is an important medical event\n\n3. REPORTING TIMELINES",
    "char_count": 353,
    "word_count": 50,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_7db0a008189d",
    "chunk_index": 2,
    "text": "4.1 SAE Identification\na) Investigator identifies SAE\nb) Assess seriousness criteria\nc) Determine relationship to study drug\nd) Document in source records",
    "char_count": 154,
    "word_count": 22,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_number": "4.1",
      "section_title": "SAE Identification",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a05ce9846e08",
    "chunk_index": 3,
    "text": "4.3 SAE Form Completion\nRequired information:\n- Subject identifier\n- Event description\n- Onset and resolution dates\n- Seriousness criteria\n- Severity (mild/moderate/severe)\n- Relationship to study drug\n- Action taken with study drug\n- Outcome\n- Reporter information",
    "char_count": 265,
    "word_count": 39,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_number": "4.3",
      "section_title": "SAE Form Completion",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_204a58d83129",
    "chunk_index": 4,
    "text": "4.4 Follow-up Reporting\na) Gather additional information\nb) Update SAE form\nc) Document resolution\nd) Submit follow-up report\n\n5. REGULATORY REPORTING",
    "char_count": 150,
    "word_count": 21,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_number": "4.4",
      "section_title": "Follow-up Reporting",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a1455310b19c",
    "chunk_index": 5,
    "text": "5.2 IRB/IEC Notification\n- Per IRB requirements\n- Annual safety reports\n- Significant safety issues\n\n6. RECONCILIATION\n- Compare DM and Safety databases\n- Identify discrepancies\n- Resolve within 5 business days\n- Document reconciliation\n\n7. QUALITY CONTROL\n- Daily review of new SAEs\n- Weekly reconciliation check\n- Monthly compliance review\n- Quarterly audit",
    "char_count": 359,
    "word_count": 55,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-001",
      "title": "Serious Adverse Event Reporting",
      "version": "5.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE",
        "serious adverse event",
        "safety reporting",
        "pharmacovigilance",
        "expedited"
      ],
      "roles": [
        "Investigator",
        "Site Coordinator",
        "Safety Officer",
        "Medical Monitor"
      ],
      "section_number": "5.2",
      "section_title": "IRB/IEC Notification",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_b43d0853923d",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for reconciling SAE data between clinical and safety databases.\n\nSCOPE: This SOP applies to data management and drug safety personnel involved in SAE reconciliation.\n\n1. PURPOSE\nThis SOP describes the procedures for ensuring alignment of SAE data between data management (EDC) and drug safety databases.\n\n2. RECONCILIATION FREQUENCY\n- Ongoing: As SAEs are received\n- Formal: Monthly reconciliation\n- Pre-lock: Final reconciliation\n\n3. RECONCILIATION SCOPE",
    "char_count": 490,
    "word_count": 69,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-002",
      "title": "SAE Reconciliation Procedures",
      "version": "3.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE reconciliation",
        "safety database",
        "discrepancy",
        "alignment",
        "data management"
      ],
      "roles": [
        "Data Manager",
        "Safety Data Manager",
        "Medical Monitor"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_65046ae50943",
    "chunk_index": 1,
    "text": "3.1 Data Points to Reconcile\n- SAE presence (listed in both systems)\n- Subject identifier\n- Event term/description\n- Onset date\n- Resolution date\n- Outcome\n- Causality assessment\n- Seriousness criteria",
    "char_count": 201,
    "word_count": 32,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-002",
      "title": "SAE Reconciliation Procedures",
      "version": "3.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE reconciliation",
        "safety database",
        "discrepancy",
        "alignment",
        "data management"
      ],
      "roles": [
        "Data Manager",
        "Safety Data Manager",
        "Medical Monitor"
      ],
      "section_number": "3.1",
      "section_title": "Data Points to Reconcile",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a4101fd98220",
    "chunk_index": 2,
    "text": "3.3 Discrepancies Requiring Resolution\n- Missing SAE in one system\n- Different onset/resolution dates\n- Different causality assessment\n- Different outcome\n\n4. PROCEDURES",
    "char_count": 169,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-002",
      "title": "SAE Reconciliation Procedures",
      "version": "3.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE reconciliation",
        "safety database",
        "discrepancy",
        "alignment",
        "data management"
      ],
      "roles": [
        "Data Manager",
        "Safety Data Manager",
        "Medical Monitor"
      ],
      "section_number": "3.3",
      "section_title": "Discrepancies Requiring Resolution",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e9c9439c159a",
    "chunk_index": 3,
    "text": "4.1 Data Extraction\na) Export SAE listing from EDC\nb) Export SAE listing from safety database\nc) Match on subject ID and event\nd) Identify discrepancies",
    "char_count": 152,
    "word_count": 26,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-002",
      "title": "SAE Reconciliation Procedures",
      "version": "3.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE reconciliation",
        "safety database",
        "discrepancy",
        "alignment",
        "data management"
      ],
      "roles": [
        "Data Manager",
        "Safety Data Manager",
        "Medical Monitor"
      ],
      "section_number": "4.1",
      "section_title": "Data Extraction",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_4b125b210ae6",
    "chunk_index": 4,
    "text": "4.4 Documentation\n- Reconciliation log maintained\n- Discrepancies documented\n- Resolutions recorded\n- Sign-off obtained\n\n5. ESCALATION\n- Day 3: DM/Safety follow-up\n- Day 7: Manager notification\n- Day 14: Study lead escalation\n\n6. METRICS\n- Reconciliation rate\n- Time to resolution\n- Discrepancy types\n- Repeat discrepancies\n\n7. PRE-LOCK REQUIREMENTS\n- 100% reconciliation complete\n- All discrepancies resolved\n- Sign-off from DM and Safety\n- Documentation archived",
    "char_count": 464,
    "word_count": 68,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-002",
      "title": "SAE Reconciliation Procedures",
      "version": "3.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "SAE reconciliation",
        "safety database",
        "discrepancy",
        "alignment",
        "data management"
      ],
      "roles": [
        "Data Manager",
        "Safety Data Manager",
        "Medical Monitor"
      ],
      "section_number": "4.4",
      "section_title": "Documentation",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_498304fa6ba5",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for detecting and responding to safety signals in clinical trials.\n\nSCOPE: This SOP applies to drug safety, medical monitoring, and clinical operations personnel.\n\n1. PURPOSE\nThis SOP describes the procedures for identifying, evaluating, and responding to safety signals during clinical trial conduct.\n\n2. SIGNAL DEFINITION\nA safety signal is information about a new or known adverse event that may require further investigation or action.",
    "char_count": 474,
    "word_count": 68,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-003",
      "title": "Safety Signal Detection and Response",
      "version": "2.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "safety signal",
        "detection",
        "surveillance",
        "pharmacovigilance",
        "DSMB"
      ],
      "roles": [
        "Safety Officer",
        "Medical Monitor",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_b93ecd96d78c",
    "chunk_index": 1,
    "text": "3. SIGNAL SOURCES\n- Individual case reports\n- Aggregate data analysis\n- Literature reports\n- Regulatory notifications\n- Investigator reports\n- DSMB recommendations\n\n4. DETECTION METHODS",
    "char_count": 185,
    "word_count": 26,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-003",
      "title": "Safety Signal Detection and Response",
      "version": "2.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "safety signal",
        "detection",
        "surveillance",
        "pharmacovigilance",
        "DSMB"
      ],
      "roles": [
        "Safety Officer",
        "Medical Monitor",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_f09260618503",
    "chunk_index": 2,
    "text": "6.1 Actions May Include\n- Enhanced monitoring\n- Protocol amendment\n- Informed consent update\n- Investigator notification\n- Regulatory notification\n- Study suspension/termination",
    "char_count": 177,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-003",
      "title": "Safety Signal Detection and Response",
      "version": "2.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "safety signal",
        "detection",
        "surveillance",
        "pharmacovigilance",
        "DSMB"
      ],
      "roles": [
        "Safety Officer",
        "Medical Monitor",
        "Study Manager"
      ],
      "section_number": "6.1",
      "section_title": "Actions May Include",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9b636040aa0c",
    "chunk_index": 3,
    "text": "6.2 Communication\n- Internal stakeholders\n- Investigators\n- IRBs/IECs\n- Regulatory authorities\n- DSMB\n\n7. ONGOING SURVEILLANCE\n- Continue monitoring after initial response\n- Track signal over time\n- Update assessment as needed\n- Document resolution\n\n8. DOCUMENTATION\n- Signal detection log\n- Evaluation reports\n- Action documentation\n- Communication records",
    "char_count": 357,
    "word_count": 51,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SA-003",
      "title": "Safety Signal Detection and Response",
      "version": "2.0",
      "department": "Drug Safety",
      "category": "safety",
      "keywords": [
        "safety signal",
        "detection",
        "surveillance",
        "pharmacovigilance",
        "DSMB"
      ],
      "roles": [
        "Safety Officer",
        "Medical Monitor",
        "Study Manager"
      ],
      "section_number": "6.2",
      "section_title": "Communication",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d7ae04c86950",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for selecting and initiating clinical trial sites.\n\nSCOPE: This SOP applies to clinical operations personnel involved in site selection and initiation.\n\n1. PURPOSE\nThis SOP describes the procedures for selecting appropriate sites and initiating them for clinical trial participation.\n\n2. SITE SELECTION",
    "char_count": 337,
    "word_count": 46,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-001",
      "title": "Site Selection and Initiation",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site selection",
        "initiation",
        "SIV",
        "feasibility",
        "activation"
      ],
      "roles": [
        "CTM",
        "CRA",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_725b629d3ac9",
    "chunk_index": 1,
    "text": "2.1 Selection Criteria\n- Investigator qualifications\n- Patient population access\n- Facility capabilities\n- Staff experience\n- Regulatory compliance history\n- Previous performance (if applicable)",
    "char_count": 194,
    "word_count": 25,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-001",
      "title": "Site Selection and Initiation",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site selection",
        "initiation",
        "SIV",
        "feasibility",
        "activation"
      ],
      "roles": [
        "CTM",
        "CRA",
        "Study Manager"
      ],
      "section_number": "2.1",
      "section_title": "Selection Criteria",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_3b0265a24a6b",
    "chunk_index": 2,
    "text": "2.2 Feasibility Assessment\na) Questionnaire completion\nb) Patient database review\nc) Competitive trial assessment\nd) Resource evaluation\ne) Site visit (if needed)",
    "char_count": 162,
    "word_count": 22,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-001",
      "title": "Site Selection and Initiation",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site selection",
        "initiation",
        "SIV",
        "feasibility",
        "activation"
      ],
      "roles": [
        "CTM",
        "CRA",
        "Study Manager"
      ],
      "section_number": "2.2",
      "section_title": "Feasibility Assessment",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_6a37543aaa0a",
    "chunk_index": 3,
    "text": "4.3 Post-SIV\n- Complete SIV report\n- Document training\n- Confirm site activation\n- Update tracking systems\n\n5. SITE ACTIVATION\n- All essential documents complete\n- Training documented\n- IP received\n- EDC access verified\n- Activation letter issued\n\n6. DOCUMENTATION\n- Feasibility records\n- Selection decision\n- SIV report\n- Activation confirmation",
    "char_count": 346,
    "word_count": 53,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-001",
      "title": "Site Selection and Initiation",
      "version": "3.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site selection",
        "initiation",
        "SIV",
        "feasibility",
        "activation"
      ],
      "roles": [
        "CTM",
        "CRA",
        "Study Manager"
      ],
      "section_number": "4.3",
      "section_title": "Post-SIV",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_0a67fbc90cf5",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for monitoring and managing site performance during clinical trials.\n\nSCOPE: This SOP applies to CRAs, CTMs, and clinical operations personnel responsible for site oversight.\n\n1. PURPOSE\nThis SOP describes the procedures for assessing, monitoring, and improving site performance throughout the clinical trial.\n\n2. PERFORMANCE METRICS",
    "char_count": 368,
    "word_count": 49,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-002",
      "title": "Site Performance Management",
      "version": "2.5",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site performance",
        "metrics",
        "improvement",
        "monitoring",
        "escalation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_458dbe786cc1",
    "chunk_index": 1,
    "text": "3.5 Needs Improvement (Bottom 10%)\n- Significant concerns\n- Intensive monitoring\n- Remediation required\n- Potential closure\n\n4. PERFORMANCE IMPROVEMENT",
    "char_count": 151,
    "word_count": 20,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-002",
      "title": "Site Performance Management",
      "version": "2.5",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site performance",
        "metrics",
        "improvement",
        "monitoring",
        "escalation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "3.5",
      "section_title": "Needs Improvement (Bottom 10%)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e6ffb6f6eb08",
    "chunk_index": 2,
    "text": "5.2 Process\n- CTM notification\n- Study lead involvement\n- Sponsor notification (if needed)\n- Site closure evaluation\n\n6. DOCUMENTATION\n- Performance reports\n- Action plans\n- Meeting minutes\n- Improvement tracking",
    "char_count": 212,
    "word_count": 32,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-002",
      "title": "Site Performance Management",
      "version": "2.5",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "site performance",
        "metrics",
        "improvement",
        "monitoring",
        "escalation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "5.2",
      "section_title": "Process",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_bae7226be2d9",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for escalating and resolving site issues during clinical trials.\n\nSCOPE: This SOP applies to all personnel involved in site management and issue resolution.\n\n1. PURPOSE\nThis SOP describes the procedures for identifying, escalating, and resolving site issues in clinical trials.\n\n2. ISSUE CATEGORIES",
    "char_count": 333,
    "word_count": 47,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-003",
      "title": "Site Issue Escalation and Resolution",
      "version": "2.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "escalation",
        "site issues",
        "resolution",
        "compliance",
        "remediation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_4f58ae0b3665",
    "chunk_index": 1,
    "text": "3.5 Level 5: Closure Consideration (Day 30+)\n- Failed remediation\n- Continued non-compliance\n- Closure evaluation\n- Subject transfer planning\n\n4. RESOLUTION PROCEDURES",
    "char_count": 167,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-003",
      "title": "Site Issue Escalation and Resolution",
      "version": "2.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "escalation",
        "site issues",
        "resolution",
        "compliance",
        "remediation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "3.5",
      "section_title": "Level 5: Closure Consideration (Day 30+)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7228ffd7fb76",
    "chunk_index": 2,
    "text": "5.2 Closure Activities\n- Transfer subjects (if applicable)\n- Collect essential documents\n- IP return\n- Close-out visit\n- Final documentation\n\n6. DOCUMENTATION\n- Issue log\n- Escalation communications\n- Action plans\n- Resolution documentation",
    "char_count": 240,
    "word_count": 35,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-SI-003",
      "title": "Site Issue Escalation and Resolution",
      "version": "2.0",
      "department": "Clinical Operations",
      "category": "site_management",
      "keywords": [
        "escalation",
        "site issues",
        "resolution",
        "compliance",
        "remediation"
      ],
      "roles": [
        "CRA",
        "CTM",
        "Study Manager"
      ],
      "section_number": "5.2",
      "section_title": "Closure Activities",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_cbbae20db43c",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for managing the Trial Master File throughout the clinical trial.\n\nSCOPE: This SOP applies to all personnel responsible for TMF documentation and maintenance.\n\n1. PURPOSE\nThis SOP describes the procedures for creating, maintaining, and archiving the Trial Master File (TMF).\n\n2. TMF STRUCTURE",
    "char_count": 327,
    "word_count": 47,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_0ba49e63a6b4",
    "chunk_index": 1,
    "text": "2.1 ICH E6(R2) Reference Model\n- Zone 01: Trial Management\n- Zone 02: Central Trial Documents\n- Zone 03: Regulatory\n- Zone 04: IRB/IEC\n- Zone 05: Site Management\n- Zone 06: IP\n- Zone 07: Safety Reporting\n- Zone 08: Statistics\n- Zone 09: Data Management",
    "char_count": 252,
    "word_count": 47,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_number": "2.1",
      "section_title": "ICH E6(R2) Reference Model",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d1c5d5cb457a",
    "chunk_index": 2,
    "text": "3.1 Document Requirements (ALCOA+)\n- Attributable: Author identifiable\n- Legible: Readable and clear\n- Contemporaneous: Created at time of event\n- Original: Certified copies acceptable\n- Accurate: Reflects actual events\n- Complete: All required documents present\n- Consistent: No contradictions\n- Enduring: Retained for required period\n- Available: Accessible when needed",
    "char_count": 371,
    "word_count": 51,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_number": "3.1",
      "section_title": "Document Requirements (ALCOA+)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_15b21fb1d4ce",
    "chunk_index": 3,
    "text": "3.2 Filing Requirements\n- Correct location per taxonomy\n- Proper naming convention\n- Complete metadata\n- Version controlled\n- Signed/dated as required\n\n4. TMF MAINTENANCE",
    "char_count": 170,
    "word_count": 25,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_number": "3.2",
      "section_title": "Filing Requirements",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_da11f1b29604",
    "chunk_index": 4,
    "text": "4.2 Inspection Readiness\n- Document inventory current\n- Cross-references complete\n- Filing consistent\n- Gaps identified and addressed\n\n5. eTMF CONSIDERATIONS",
    "char_count": 157,
    "word_count": 21,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_number": "4.2",
      "section_title": "Inspection Readiness",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_67580473a646",
    "chunk_index": 5,
    "text": "5.2 User Responsibilities\n- Use correct naming conventions\n- Complete all metadata\n- Upload timely\n- Verify upload success\n\n6. QUALITY CONTROL\n- Weekly filing compliance check\n- Monthly completeness review\n- Quarterly TMF audit\n- Annual system validation\n\n7. ARCHIVING\n- Per retention requirements\n- Secure storage\n- Accessibility maintained\n- Destruction procedures documented",
    "char_count": 377,
    "word_count": 55,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-001",
      "title": "Trial Master File Management",
      "version": "3.5",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "TMF",
        "trial master file",
        "essential documents",
        "filing",
        "archiving"
      ],
      "roles": [
        "Document Manager",
        "CRA",
        "Quality Assurance"
      ],
      "section_number": "5.2",
      "section_title": "User Responsibilities",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_d9d7aaca3561",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for retaining and archiving clinical trial documents.\n\nSCOPE: This SOP applies to all personnel responsible for document retention and archival.\n\n1. PURPOSE\nThis SOP describes the procedures for retaining clinical trial documents and transferring them to archive.\n\n2. RETENTION REQUIREMENTS",
    "char_count": 325,
    "word_count": 44,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-002",
      "title": "Document Retention and Archiving",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "retention",
        "archiving",
        "storage",
        "destruction",
        "records management"
      ],
      "roles": [
        "Document Manager",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_520e23c08bd5",
    "chunk_index": 1,
    "text": "2.1 Regulatory Requirements\n- ICH: 2 years after last approval or discontinuation\n- FDA: 2 years after marketing approval\n- EMA: 25 years after study completion\n- Apply longest applicable requirement",
    "char_count": 199,
    "word_count": 31,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-002",
      "title": "Document Retention and Archiving",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "retention",
        "archiving",
        "storage",
        "destruction",
        "records management"
      ],
      "roles": [
        "Document Manager",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_number": "2.1",
      "section_title": "Regulatory Requirements",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_c07e9818b43f",
    "chunk_index": 2,
    "text": "4.2 Electronic Archives\n- Validated systems\n- Backup procedures\n- Media migration plan\n- Accessibility verified\n\n5. RETRIEVAL PROCEDURES\n- Formal request required\n- Authorization verified\n- Retrieval documented\n- Return tracked\n\n6. DESTRUCTION PROCEDURES",
    "char_count": 254,
    "word_count": 35,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-002",
      "title": "Document Retention and Archiving",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "retention",
        "archiving",
        "storage",
        "destruction",
        "records management"
      ],
      "roles": [
        "Document Manager",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_number": "4.2",
      "section_title": "Electronic Archives",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_21c318711104",
    "chunk_index": 3,
    "text": "6.2 Process\n- Destruction method appropriate\n- Witnessed if required\n- Certificate obtained\n- Documentation updated\n\n7. DOCUMENTATION\n- Retention schedule\n- Archive inventory\n- Retrieval log\n- Destruction certificates",
    "char_count": 217,
    "word_count": 30,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-ES-002",
      "title": "Document Retention and Archiving",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "essential_documents",
      "keywords": [
        "retention",
        "archiving",
        "storage",
        "destruction",
        "records management"
      ],
      "roles": [
        "Document Manager",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_number": "6.2",
      "section_title": "Process",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ce865a40c92e",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for reviewing electronic audit trails in clinical trials.\n\nSCOPE: This SOP applies to data management and quality assurance personnel responsible for audit trail review.\n\n1. PURPOSE\nThis SOP describes the procedures for reviewing audit trails to ensure data integrity and regulatory compliance.\n\n2. AUDIT TRAIL REQUIREMENTS",
    "char_count": 358,
    "word_count": 50,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-001",
      "title": "Audit Trail Review Procedures",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "audit trail",
        "review",
        "data integrity",
        "21 CFR Part 11",
        "compliance"
      ],
      "roles": [
        "Data Manager",
        "Quality Assurance",
        "Compliance Officer"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_ad502dd1bc49",
    "chunk_index": 1,
    "text": "2.2 Required Elements\n- User identification\n- Date and time stamp\n- Previous value\n- New value\n- Reason for change (if applicable)\n\n3. REVIEW FREQUENCY\n- Routine: Monthly sample review\n- For-cause: Upon request\n- Pre-lock: Comprehensive review\n- Inspection: As requested\n\n4. REVIEW PROCEDURES",
    "char_count": 292,
    "word_count": 46,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-001",
      "title": "Audit Trail Review Procedures",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "audit trail",
        "review",
        "data integrity",
        "21 CFR Part 11",
        "compliance"
      ],
      "roles": [
        "Data Manager",
        "Quality Assurance",
        "Compliance Officer"
      ],
      "section_number": "2.2",
      "section_title": "Required Elements",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_16bcac2455e2",
    "chunk_index": 2,
    "text": "4.2 Review Activities\na) Export audit trail data\nb) Review changes chronologically\nc) Identify unusual patterns\nd) Document findings\ne) Follow up on concerns",
    "char_count": 157,
    "word_count": 24,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-001",
      "title": "Audit Trail Review Procedures",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "audit trail",
        "review",
        "data integrity",
        "21 CFR Part 11",
        "compliance"
      ],
      "roles": [
        "Data Manager",
        "Quality Assurance",
        "Compliance Officer"
      ],
      "section_number": "4.2",
      "section_title": "Review Activities",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_771473235ea7",
    "chunk_index": 3,
    "text": "4.3 Red Flags\n- Excessive changes to same field\n- Changes by unauthorized users\n- Changes after database lock\n- Pattern of late changes\n- Unusual timing of changes\n\n5. DOCUMENTATION\n- Review date and reviewer\n- Records reviewed\n- Findings\n- Follow-up actions\n- Resolution\n\n6. ESCALATION\n- Significant findings to QA\n- Data integrity concerns to management\n- Potential fraud to compliance\n- Regulatory implications assessed\n\n7. TRAINING\n- Reviewers trained on procedures\n- Training documented\n- Annual refresher required",
    "char_count": 519,
    "word_count": 82,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-001",
      "title": "Audit Trail Review Procedures",
      "version": "2.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "audit trail",
        "review",
        "data integrity",
        "21 CFR Part 11",
        "compliance"
      ],
      "roles": [
        "Data Manager",
        "Quality Assurance",
        "Compliance Officer"
      ],
      "section_number": "4.3",
      "section_title": "Red Flags",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_e5ff00e91ddc",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for preparing for and responding to regulatory inspections.\n\nSCOPE: This SOP applies to all personnel who may be involved in regulatory inspections.\n\n1. PURPOSE\nThis SOP describes the procedures for preparing for regulatory inspections and responding to inspection findings.\n\n2. INSPECTION TYPES\n- FDA BIMO inspection\n- EMA GCP inspection\n- National authority inspection\n- For-cause inspection\n- Pre-approval inspection\n\n3. INSPECTION PREPARATION",
    "char_count": 481,
    "word_count": 67,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-002",
      "title": "Inspection Preparation and Response",
      "version": "3.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "inspection",
        "preparation",
        "response",
        "CAPA",
        "regulatory",
        "FDA"
      ],
      "roles": [
        "Quality Assurance",
        "Study Manager",
        "Site Coordinator"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_cead494edcff",
    "chunk_index": 1,
    "text": "3.2 Pre-Inspection Activities\n- Designate inspection coordinator\n- Review TMF completeness\n- Prepare inspection room\n- Brief staff on procedures\n- Prepare key documents",
    "char_count": 168,
    "word_count": 24,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-002",
      "title": "Inspection Preparation and Response",
      "version": "3.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "inspection",
        "preparation",
        "response",
        "CAPA",
        "regulatory",
        "FDA"
      ],
      "roles": [
        "Quality Assurance",
        "Study Manager",
        "Site Coordinator"
      ],
      "section_number": "3.2",
      "section_title": "Pre-Inspection Activities",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_404a7c23c613",
    "chunk_index": 2,
    "text": "3.3 Staff Preparation\n- Review roles and responsibilities\n- Protocol refresher\n- Procedure review\n- Mock questions\n- Communication guidelines\n\n4. DURING INSPECTION",
    "char_count": 163,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-002",
      "title": "Inspection Preparation and Response",
      "version": "3.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "inspection",
        "preparation",
        "response",
        "CAPA",
        "regulatory",
        "FDA"
      ],
      "roles": [
        "Quality Assurance",
        "Study Manager",
        "Site Coordinator"
      ],
      "section_number": "3.3",
      "section_title": "Staff Preparation",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ef6f8f6c3e8a",
    "chunk_index": 3,
    "text": "4.2 Conduct\n- Professional and cooperative\n- Answer questions directly\n- Provide requested documents promptly\n- Do not volunteer information\n- Take detailed notes\n- Clarify questions if unclear",
    "char_count": 193,
    "word_count": 29,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-002",
      "title": "Inspection Preparation and Response",
      "version": "3.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "inspection",
        "preparation",
        "response",
        "CAPA",
        "regulatory",
        "FDA"
      ],
      "roles": [
        "Quality Assurance",
        "Study Manager",
        "Site Coordinator"
      ],
      "section_number": "4.2",
      "section_title": "Conduct",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_8989c6b05df5",
    "chunk_index": 4,
    "text": "5.3 CAPA Development\n- Root cause analysis\n- Corrective actions\n- Preventive actions\n- Implementation plan\n- Effectiveness monitoring\n\n6. DOCUMENTATION\n- Inspection log\n- Request/response tracking\n- Finding summaries\n- CAPA documentation\n- Response submissions",
    "char_count": 260,
    "word_count": 36,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-AU-002",
      "title": "Inspection Preparation and Response",
      "version": "3.0",
      "department": "Quality Assurance",
      "category": "audit",
      "keywords": [
        "inspection",
        "preparation",
        "response",
        "CAPA",
        "regulatory",
        "FDA"
      ],
      "roles": [
        "Quality Assurance",
        "Study Manager",
        "Site Coordinator"
      ],
      "section_number": "5.3",
      "section_title": "CAPA Development",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_9b8d33ae4614",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for maintaining regulatory compliance throughout clinical trials.\n\nSCOPE: This SOP applies to regulatory affairs, clinical operations, and quality assurance personnel.\n\n1. PURPOSE\nThis SOP describes the procedures for ensuring and maintaining regulatory compliance in clinical trial conduct.\n\n2. REGULATORY FRAMEWORK",
    "char_count": 351,
    "word_count": 44,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-RE-001",
      "title": "Regulatory Compliance Procedures",
      "version": "4.0",
      "department": "Regulatory Affairs",
      "category": "regulatory",
      "keywords": [
        "regulatory",
        "compliance",
        "GCP",
        "FDA",
        "ICH",
        "IRB"
      ],
      "roles": [
        "Regulatory Affairs",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_5d599bd36ffa",
    "chunk_index": 1,
    "text": "5.3 Correction\n- Immediate correction\n- Preventive measures\n- Documentation\n- Follow-up verification\n\n6. TRAINING\n- GCP training required\n- Protocol-specific training\n- SOP training\n- Refresher training\n- Documentation maintained\n\n7. DOCUMENTATION\n- Training records\n- Compliance assessments\n- CAPA documentation\n- Regulatory correspondence",
    "char_count": 340,
    "word_count": 45,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-RE-001",
      "title": "Regulatory Compliance Procedures",
      "version": "4.0",
      "department": "Regulatory Affairs",
      "category": "regulatory",
      "keywords": [
        "regulatory",
        "compliance",
        "GCP",
        "FDA",
        "ICH",
        "IRB"
      ],
      "roles": [
        "Regulatory Affairs",
        "Quality Assurance",
        "Study Manager"
      ],
      "section_number": "5.3",
      "section_title": "Correction",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ca33a6533235",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for ensuring compliance with 21 CFR Part 11 requirements.\n\nSCOPE: This SOP applies to all personnel using electronic systems for clinical trial records.\n\n1. PURPOSE\nThis SOP describes the procedures for ensuring that electronic records and electronic signatures meet 21 CFR Part 11 requirements.\n\n2. SCOPE OF APPLICATION",
    "char_count": 355,
    "word_count": 52,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-RE-002",
      "title": "21 CFR Part 11 Compliance",
      "version": "2.5",
      "department": "Quality Assurance",
      "category": "regulatory",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "electronic signatures",
        "validation",
        "audit trail"
      ],
      "roles": [
        "IT",
        "Quality Assurance",
        "Data Management"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_36406f2ab4db",
    "chunk_index": 1,
    "text": "2.1 Covered Records\n- Electronic records that are GxP regulated\n- Electronic signatures used in lieu of handwritten\n- Hybrid systems (paper + electronic)",
    "char_count": 153,
    "word_count": 24,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-RE-002",
      "title": "21 CFR Part 11 Compliance",
      "version": "2.5",
      "department": "Quality Assurance",
      "category": "regulatory",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "electronic signatures",
        "validation",
        "audit trail"
      ],
      "roles": [
        "IT",
        "Quality Assurance",
        "Data Management"
      ],
      "section_number": "2.1",
      "section_title": "Covered Records",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_800faf30a675",
    "chunk_index": 2,
    "text": "4.3 Signature Manifestation (11.50)\n- Printed name\n- Date and time\n- Meaning of signature\n\n5. COMPLIANCE PROCEDURES\n- System assessment\n- Gap analysis\n- Remediation\n- Ongoing monitoring\n\n6. DOCUMENTATION\n- Validation documentation\n- Training records\n- Procedure documentation\n- Audit trail access",
    "char_count": 297,
    "word_count": 44,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-RE-002",
      "title": "21 CFR Part 11 Compliance",
      "version": "2.5",
      "department": "Quality Assurance",
      "category": "regulatory",
      "keywords": [
        "21 CFR Part 11",
        "electronic records",
        "electronic signatures",
        "validation",
        "audit trail"
      ],
      "roles": [
        "IT",
        "Quality Assurance",
        "Data Management"
      ],
      "section_number": "4.3",
      "section_title": "Signature Manifestation (11.50)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_eccbc1a266b6",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for coding adverse events and medical history using MedDRA.\n\nSCOPE: This SOP applies to medical coders and data management personnel involved in AE/MH coding.\n\n1. PURPOSE\nThis SOP describes the procedures for coding adverse events and medical history terms using the Medical Dictionary for Regulatory Activities (MedDRA).\n\n2. CODING DICTIONARIES",
    "char_count": 380,
    "word_count": 54,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-001",
      "title": "Medical Coding Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "MedDRA",
        "coding",
        "adverse events",
        "medical history",
        "PT",
        "LLT"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_adc641a96333",
    "chunk_index": 1,
    "text": "3.2 Coding Assignment\na) Search dictionary for matching term\nb) Select most specific appropriate term\nc) Code to LLT/PT level\nd) Verify SOC assignment\ne) Document coding decision",
    "char_count": 178,
    "word_count": 28,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-001",
      "title": "Medical Coding Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "MedDRA",
        "coding",
        "adverse events",
        "medical history",
        "PT",
        "LLT"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "3.2",
      "section_title": "Coding Assignment",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_7e8d95045bf9",
    "chunk_index": 2,
    "text": "3.3 Coding Guidelines\n- Code to reported term, not diagnosis\n- Use most specific term available\n- Avoid assumptions\n- Query if uncertain\n- Document rationale\n\n4. CODING LEVELS",
    "char_count": 175,
    "word_count": 29,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-001",
      "title": "Medical Coding Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "MedDRA",
        "coding",
        "adverse events",
        "medical history",
        "PT",
        "LLT"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "3.3",
      "section_title": "Coding Guidelines",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_5b1ce12fceae",
    "chunk_index": 3,
    "text": "4.3 System Organ Class (SOC)\n- Highest grouping level\n- Used for reporting\n- Primary SOC assigned\n\n5. AUTO-CODING\n- System suggests codes for common terms\n- Coder verifies suggestions\n- Acceptance or override documented\n- High-confidence threshold defined\n\n6. QUALITY CONTROL\n- Daily review of coded terms\n- Batch review before lock\n- Consistency checks\n- Inter-coder reliability\n\n7. DOCUMENTATION\n- Coding conventions document\n- Decision log\n- Query documentation\n- Version history",
    "char_count": 482,
    "word_count": 74,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-001",
      "title": "Medical Coding Procedures",
      "version": "3.0",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "MedDRA",
        "coding",
        "adverse events",
        "medical history",
        "PT",
        "LLT"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "4.3",
      "section_title": "System Organ Class (SOC)",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_ba90561aa87b",
    "chunk_index": 0,
    "text": "OBJECTIVE: To establish procedures for coding concomitant medications using WHODrug.\n\nSCOPE: This SOP applies to medical coders and data management personnel involved in drug coding.\n\n1. PURPOSE\nThis SOP describes the procedures for coding concomitant medications and prior therapies using the WHODrug dictionary.\n\n2. CODING DICTIONARY",
    "char_count": 335,
    "word_count": 46,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_type": "introduction"
    }
  },
  {
    "chunk_id": "chunk_672aad313e2b",
    "chunk_index": 1,
    "text": "3.1 Drug Name Review\na) Review drug name from CRF\nb) Assess completeness (name, formulation, route)\nc) Query site if incomplete\nd) Consider regional variations",
    "char_count": 159,
    "word_count": 25,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "3.1",
      "section_title": "Drug Name Review",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_a6b054b4eade",
    "chunk_index": 2,
    "text": "3.2 Coding Assignment\na) Search dictionary for drug name\nb) Match on trade name or generic\nc) Verify formulation match\nd) Assign ATC code\ne) Document coding",
    "char_count": 156,
    "word_count": 27,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "3.2",
      "section_title": "Coding Assignment",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_64dac0491932",
    "chunk_index": 3,
    "text": "3.3 Coding Guidelines\n- Match trade name when available\n- Use generic for combination products\n- Consider regional brand names\n- Query for clarification if needed\n\n4. CODING LEVELS",
    "char_count": 180,
    "word_count": 29,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "3.3",
      "section_title": "Coding Guidelines",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_da0a51445e13",
    "chunk_index": 4,
    "text": "4.2 ATC Classification\n- Anatomical main group\n- Therapeutic subgroup\n- Pharmacological subgroup\n- Chemical subgroup\n- Chemical substance\n\n5. HANDLING SPECIAL CASES",
    "char_count": 164,
    "word_count": 23,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "4.2",
      "section_title": "ATC Classification",
      "section_type": "numbered"
    }
  },
  {
    "chunk_id": "chunk_487390d89a27",
    "chunk_index": 5,
    "text": "5.3 Investigational Drugs\n- Do not code study drug\n- Code other investigational per plan\n\n6. QUALITY CONTROL\n- Daily coding review\n- Batch review before lock\n- ATC code verification\n- Inter-coder reliability checks\n\n7. DOCUMENTATION\n- Coding conventions\n- Decision log\n- Query documentation\n- Version history",
    "char_count": 308,
    "word_count": 49,
    "metadata": {
      "source": "sop",
      "source_name": "Standard Operating Procedures",
      "document_type": "sop",
      "sop_id": "SOP-CD-002",
      "title": "Drug Coding Procedures",
      "version": "2.5",
      "department": "Data Management",
      "category": "coding",
      "keywords": [
        "WHODrug",
        "drug coding",
        "concomitant medications",
        "ATC",
        "pharmaceutical"
      ],
      "roles": [
        "Medical Coder",
        "Data Manager"
      ],
      "section_number": "5.3",
      "section_title": "Investigational Drugs",
      "section_type": "numbered"
    }
  }
]